



(86) Date de dépôt PCT/PCT Filing Date: 1994/03/28
(87) Date publication PCT/PCT Publication Date: 1994/10/13
(45) Date de délivrance/Issue Date: 2005/06/28
(85) Entrée phase nationale/National Entry: 1995/09/25
(86) N° demande PCT/PCT Application No.: US 1994/003329
(87) N° publication PCT/PCT Publication No.: 1994/022823
(30) Priorités/Priorities: 1993/03/26 (08/038,571) US;
1993/07/29 (08/099,965) US; 1993/12/23 (08/173,586) US

(51) Cl.Int.⁶/Int.Cl.⁶ C07D 209/44, A61K 31/44, A61K 31/40,
C07D 409/04, C07D 401/04






(72) Inventeurs/Inventors:
CARMOSIN, RICHARD J., US;
CARSON, JOHN R., US;
LIOTTA, DENNIS C., US;
PITIS, PHILIP, US;
RAFFA, ROBERT B., US

(73) Propriétaire/Owner:
ORTHO PHARMACEUTICAL CORPORATION, US

(74) Agent: OGILVY RENAULT

(54) Titre : ANALGESIQUES DE TYPE 4-ARYLISOINDOLE

(54) Title: 4-ARYLISOINDOLE ANALGESICS



(57) Abrégé/Abstract:

The 4-arylisoindoles of formula (I) are effective analgesics including stereoisomers and pharmaceutically acceptable salts thereof, wherein (II) is (III), (IV) or (V); with the proviso that there is 0 or 1 unsaturated bond in the isoindole ring and with the proviso that where the stereoisomer is: a) the 3a β , 4 β , 7a α diastereomer, then a double bond joins the 5- and 6-position carbons or the 6- and 7-position carbons; b) the 3a β , 4 α , 7a α or the 3a β , 4 α , 7a β diastereomers, then the double bond joins the 5- and 6-position carbons; and c) the 3a β , 4 β , 7a β diastereomer, then the double bond joins the 6- and 7-position carbons.








INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 209/44, 401/04, 409/04, A61K 31/40, 31/44		A1	(11) International Publication Number: WO 94/22823 (43) International Publication Date: 13 October 1994 (13.10.94)
(21) International Application Number: PCT/US94/03329 (22) International Filing Date: 28 March 1994 (28.03.94) (30) Priority Data: 08/038,571 26 March 1993 (26.03.93) US 08/099,965 29 July 1993 (29.07.93) US 08/173,586 23 December 1993 (23.12.93) US (71) Applicant: ORTHO PHARMACEUTICAL CORPORATION [US/US]; U.S. Route #206, Raritan, NJ 08869-0602 (US). (72) Inventors: CARMOSIN, Richard, J.; 122 Woodview Drive, Quakertown, PA 18951 (US). CARSON, John, R.; 551 Rit- tenhouse Boulevard, Norristown, PA 19403 (US). LIOTTA, Dennis, C.; 251 Montrose Drive, McDonough, GA 30253 (US). PITIS, Philip; 108 Sunrise Drive, North Wales, PA 19454 (US). RAFFA, Robert, B.; 4 Pacer Lane, Norristown, PA 19401 (US). (74) Agents: CIAMPORCERO, Audley, A. et al.; Johnson and Johnson, One Johnson and Johnson Plaza, New Brunswick, NJ 08933-7003 (US).			(81) Designated States: AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SE, SI, SK, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.

2159071

(54) Title: 4-ARYLISOINDOLE ANALGESICS



(57) Abstract

The 4-arylisoindoles of formula (I) are effective analgesics including stereoisomers and pharmaceutically acceptable salts thereof, wherein (II) is (III), (IV) or (V); with the proviso that there is 0 or 1 unsaturated bond in the isoindole ring and with the proviso that where the stereoisomer is: a) the 3a β , 4 β , 7a α diastereomer, then a double bond joins the 5- and 6-position carbons or the 6- and 7-position carbons; b) the 3a β , 4 α , 7a α or the 3a β , 4 α , 7a β diastereomers, then the double bond joins the 5- and 6-position carbons; and c) the 3a β , 4 β , 7a β diastereomer, then the double bond joins the 6- and 7-position carbons.

4-ARYLISOINDOLE ANALGESICS

5

The present invention relates to analgesics. More particularly, the present invention relates to 4-aryl(octahydro or hexahydro)-1H-isoindoles having analgesic activity.

10


BACKGROUND OF THE INVENTION

15

Analgesics used today in clinical practice suffer either from limited efficacy, limiting side effects or both. The non-steroidal antiinflammatory agents such as aspirin and ibuprofen fail to treat severe pain and cause gastrointestinal side effects. The opiates (morphine, codeine or meperidine) can treat more severe pain, but are subject to addiction liability and cause constipation and respiratory depression.


Eur. Pat. No. 430 771, to Rhone Polenc, discloses the compound:

2159071




The biological utility is disclosed as a Substance P antagonist.

Ciba-Giegy has publicly disclosed the compound:



- 5 However, no biological activity was taught for this compound and its suitability for use as an analgesic is unknown.


U.S. Pat. No. 5,216,018, to Ciganek discloses isoindoles of the formula:




- 10 wherein R² and R³ are disclosed among many other substituents to be independently phenyl. These compounds are disclosed as useful to treat physiological or drug induced psychosis and as antidyskinetic agents.

SUMMARY OF THE INVENTION

The present invention provides novel octahydro or hexahydro-1H-isoindoles having analgesic activity of the formula:



- 5 including the purified stereoisomers and pharmaceutically acceptable salts thereof,
wherein



10 R^{a1} is selected from the group consisting of hydroxy, halogen, C₁-4alkyl, substituted C₁-4alkyl (wherein the substituent is C₁-4alkoxy, hydroxy or perhalo), C₁-4alkoxy, substituted C₁-4alkoxy (wherein the substituent is perfluoro), C₁-4alkylthio, cyano, nitro, amino, C₁-4alkylamino, diC₁-4alkylamino, C₁-4alkylsulfonyl, C₁-4alkylsulfinyl, phenyl, phenylthio, C₁-4acylamino, carboxy,
15 C₁-4acyl and benzoyl;

R^{a2} is selected from the group consisting of halogen or C₁-4alkyl;

R^b is 5-, 6-, or 7-position substituted and selected from the group consisting of hydrogen and C₁-4 alkyl; and

20 R^c is selected from the group consisting of hydrogen, C₁-4 alkyl, substituted C₁-4alkyl (wherein the substituent is one or two phenyl groups or

diC₁₋₄alkylamino), C₂₋₄alkenyl, benzyl, C₃₋₆cycloalkylmethyl and C₃₋₆cycloalkyl;

with the proviso that there is 0 or 1 unsaturated bond in the isoindole ring and with the proviso that where the stereoisomer is:


5 a) the 3a β , 4 β , 7a α diastereomer, then a double bond joins the 5- and 6-position carbons or the 6- and 7-position carbons;

 b) the 3a β , 4 α , 7a α or the 3a β , 4 α , 7a β diastereomers, then the double bond joins the 5- and 6-position carbons; and


 c) the 3a β , 4 β , 7a β diastereomer, then the double bond joins the 6-
10 and 7-position carbons.

DETAILED DESCRIPTION OF THE INVENTION


The compounds of Formula (I) can be divided into six diastereomers:




1 3a β , 4 β , 7a α and
3a α , 4 α , 7a β




2 3a β , 4 α , 7a α and
3a α , 4 β , 7a β




3 3a β , 4 β , 7a β and
3a α , 4 α , 7a α



4 3a β , 4 α , 7a β and
3a α , 4 β , 7a α



5 3a β , 7a β and
3a α , 7a α



6 3a β , 7a α and
3a α , 7a β

where R^a , R^b and R^c are as defined above. Unless specifically indicated otherwise, the structures herein represent the depicted stereoisomer as a racemic mixture.

The manufacture of compounds of Formula (I) may be carried out in a two-stage synthesis scheme followed by a final step in which any protecting groups are removed. The objective of the first synthetic stage is to produce the desired stereoisomer of a core 4-aryl(octahydro or hexahydro)-1H-isoindole. The objective of the second synthetic stage is to substitute the core 4-aryl(octahydro or hexahydro)-1H-isoindole with desired R^a , R^b and R^c substituents (where R^a is used generically to refer to both R^{a1} and R^{a2}). Of course, persons skilled in the art will immediately realize the the two objectives are not always separable. In a first scenario, the second synthetic stage is performed initially where desired R^a , R^b and R^c are substituted on the starting materials for the core 4-aryl(octahydro or hexahydro)-1H-isoindole synthesis and carried through the synthesis unchanged. A second scenario is identical to the first except that protecting groups may be employed through the synthesis and removed thereafter. In a third scenario, precursor substituents may be added to the starting materials or any of the intermediates to the core 4-phenyl(octahydro or hexahydro)-1H-isoindole and elaborated to desired R^a , R^b and R^c substituents following formation of the core compound. In a fourth scenario, suitable R^a , R^b and R^c substituents on the core 4-aryl(octahydro or hexahydro)-1H-isoindole may themselves be further elaborated to other such substituents. Thus, the two synthetic stages may be sequentially or simultaneously performed with the separable objectives of producing the core 4-aryl(octahydro or hexahydro)-1H-isoindole and appropriate substituents thereon.


Flow Sheets AA through AE illustrate the first synthetic stage for the production of core 4-aryl(octahydro or hexahydro)-1H-isoindole. In each of the Flow Sheets, the case in which the aryl is phenyl is exemplified. The core compound of Formula I has three stereocenters and, in consequence, 2^3 or 8 stereoisomers which include 4 diastereomers. The instant invention anticipates biological activity in each of the 4 diastereomers. Thus, Flow Sheets AA through AE, illustrate syntheses by which each of the 4 diastereomers may be produced. The following is a description of the chemistry employed in each suggested procedure.

AA: Synthesis of diastereomers 1 and 3

Diastereomers 1 and 3 of Flow Scheme AA are obtained from commonly available starting materials which include pyridine or substituted pyridines and *trans*-cinnamoyl chloride or substituted *trans*-cinnamoyl chloride. Of course, the equivalent acid chloride or substituted acid chloride with pyridine or thiophene rather than phenyl would be employed in Flow Sheet AA as starting material AA3 to obtain these alternate aryl moieties at the 4-position of the desired octahydro or hexahydro-1H-isoindole. The description herein using the phenyl bearing *trans*-cinnamic acid is for exemplification only. In a first step, pyridine is converted to an N-substituted pyridinium salt AA1 by reaction with R^CI, i.e. benzyl iodide, methyl iodide, ethyl iodide, etc., forming the iodide salt. Subsequently, pyridinium salt AA1 is ring opened by refluxing in a suspension of sodium aluminum hydride or lithium aluminum hydride in a suitable solvent, such as, THF, to form *cis*-dienylamine AA2. The resulting *cis*-dienylamine AA2 might be substituted on any of carbons 1 to 5 depending upon the position of R^a on the pyridine starting material. Those compounds AA2 that are 1- or 2-R^a substituted might be conveniently separated at this point by standard techniques as they will not result in compounds of formula I. *Cis*-amine AA2 is subsequently acylated with *trans*-cinnamoyl chloride or substituted *trans*-cinnamoyl chloride AA3 to form diene/dienophile AA4. This acylation might be carried out in a suitable solvent, such as, THF, with a base, for instance, NaOH, optionally applying heat. Diene/dienophile AA4 may be ring closed in an intramolecular Diels-Alder reaction to give a mixture of bicyclic compounds AA5 and AA6. By Flow Sheet AA, isomer AA6 predominates. The intramolecular Diels-Alder reaction is preferably carried out by simply heating diene/dienophile AA4 in a high boiling organic solvent. Suitable high boiling organic solvents boil in a temperature range between 80 and 250 °C and include, for example, toluene, xylene and dichlorobenzene. The reaction might also be carried out with a lower boiling solvent in a pressure apparatus. Preferably the reaction is carried out in a temperature range between 100 and 180 °C under normal pressure. Bicyclic compounds AA5 and AA6 are consecutively hydrogenated and subjected to hydride reduction to produce 4-phenyl(octahydro or hexahydro)-1H-isoindoles 1 and 3, respectively. The hydrogenation may be carried out over Raney nickel or over a noble metal, such as, palladium, platinum, rhodium or nickel, with or without heat and at pressures from atmospheric to 1000 psi. In the case where R^a is nitro, it is preferred that the hydrogenation be carried out over

5 ruthenium. The hydride reduction is carried out with a reducing agent in a suitable organic solvent, such as, THF. Suitable reducing agents include lithium aluminum hydride, sodium diethyl aluminum hydride, borane-methylsulfide and borane-THF. Bicyclic compounds AA5 and AA6 are subjected to hydride reduction to produce the delta-6,7 isoindoles 1 and 3, respectively. In this hydride reduction, suitable reducing agents include lithium aluminum hydride and sodium diethyl aluminum hydride.

FLOW SHEET AA



AB: Synthesis of diastereomers 1 and 3

Diastereomers 1 and 3 of Flow Scheme AB are obtained from commonly available starting materials which include R^C-aminoethanol, *trans*-cinnamoyl chloride or substituted *trans*-cinnamoyl chloride and allylidenetriphenylphosphorane. Of course, the equivalent acid chloride or substituted acid chloride with pyridine or thiophene rather than phenyl would be employed in Flow Sheet AB as starting material AB2 to obtain these alternate aryl moieties at the 4-position of the desired octahydro or hexahydro-1H-isoindole. The description herein using the phenyl bearing *trans*-cinnamic acid is for exemplification only. In a first step, aminoalcohol AB1 is acylated with *trans*-cinnamoyl chloride or substituted *trans*-cinnamoyl chloride AB2 to form hydroxyamide AB3. This acylation might be carried out in a suitable solvent, such as, THF, with a base, for instance, NaOH, optionally applying heat. Hydroxyamide AB3 is converted to the corresponding aldehyde AB4 by a Swern oxidation. This oxidation may be carried out in methylene chloride at from -70 °C to room temperature employing oxalyl chloride-dimethyl sulfoxide-diethylamine. In the next step of Flow Sheet AB, reaction of aldehyde AB4 with allylidenetriphenylphosphorane AB5 affords the diene AB6. The allylidenetriphenylphosphorane is generated in solution from an allyl triphenylphosphonium halide and base. The halogen salt, allyl triphenylphosphonium bromide, is formed from a mixture of triphenylphosphine and allyl bromide upon standing for a few days. The chlorine salt would also be useful and both the chlorine and bromine halogen salts are available on the market. The Wittig reaction is carried out in a suitable organic solvent, such as, an ethereal solvent, and the salt is dehydrohalogenated by the addition of a sufficiently strong base to produce the reactive allylidenetriphenylphosphorane, AB5. Suitable bases include phenyllithium or NaN[Si(CH₃)₃]₂. The objective diene/dienophile AB6, both *cis* and *trans* at the diene, is produced upon the mixture standing at room temperature for from a few minutes to overnight with the adducts triphenylphosphine oxide and metal salt separating. Diene/dienophile AB6 may be ring closed in an intramolecular Diels-Alder reaction to give a mixture of bicyclic compounds AB7 and AB8. The intramolecular Diels-Alder reaction is preferably carried out by simply heating diene/dienophile AB6 in a high boiling organic solvent. Suitable high boiling organic solvents boil in a temperature range between 80 and 250 °C and include, for example, toluene, xylene and dichlorobenzene. The reaction might also be carried


ou: with a lower boiling solvent in a pressure apparatus. Preferably the reaction is carried out in a temperature range between 100 and 180 °C under normal pressure. Bicyclic compounds AB7 and AB8 are consecutively hydrogenated and subjected to hydride reduction to produce

5 4-phenyl-1H-isoindoles 3 and 1, respectively. The hydrogenation may be carried out over Raney nickel or over a noble metal, such as, palladium, platinum, rhodium or nickel, with or without heat and at pressures from atmospheric to 1000 psi. In the case where R^a is nitro, it is preferred that the hydrogenation be carried out over ruthenium. The hydride reduction is

10 carried out with a reducing agent in a suitable organic solvent, such as, THF. Suitable reducing agents include lithium aluminum hydride, sodium diethyl aluminum hydride, borane methylsulfide and borane-THF. Bicyclic compounds AB7 and AB8 are subjected to hydride reduction to produce the delta-6,7 isoindoles 3 and 1, respectively. In this hydride reduction, suitable

15 reducing agents include lithium aluminum hydride and sodium diethyl aluminum hydride.

FLOW SHEET AB




AC: Synthesis of diastereomers 1 and 3

Diastereomers 1 and 3 of Flow Scheme AC are obtained from commonly available starting materials which include *trans*-cinnamoyl chloride or substituted *trans*-cinnamoyl chloride and *trans*-2,4-pentadienoic acid or substituted *trans*-2,4-pentadienoic acid. Of course, the equivalent acid chloride or substituted acid chloride with pyridine or thiophene rather than phenyl would be employed in Flow Sheet AC as starting material AC5 to obtain these alternate aryl moieties at the 4-position of the desired octahydro or hexahydro-1H-isoindole. The description herein using the phenyl bearing *trans*-cinnamic acid is for exemplification only. In a first step, *trans*-dienoic acid AC1 is reduced to the corresponding alcohol AC2 in a solvent with a hydride reducing agent. Compound AC1 is available on the market or is easily prepared by persons skilled in the art. To produce desirable compounds herein, R^b of compound AC1 is a 3-, 4- or 5-position substituent. Suitable reducing agents include lithium aluminum hydride (LAH) and sodium diethylaluminum hydride. Preferred solvents for use with the named reducing agents are the ethereal solvents. Subsequently, *trans*-dienylcarbinol AC2 is oxidized or halogenated to *trans*-diene AC3 wherein Z^a is formyl or halomethyl, i.e., chloromethyl, bromomethyl or iodomethyl. The oxidation of an alcohol to an aldehyde is well known. In this instance, care must be taken in choosing an oxidation process that the oxidation is severe enough to act on the alcohol, but not so severe that the diene is also oxidized. Two alternative processes are suggested herein. In one alternative, *trans*-dienylcarbinol AC2 is reacted with the complex formed by chromium trioxide and pyridine in a halocarbon solvent to give Z^a as formyl in good yield. With excess reagent, i.e., complex, this oxidation proceeds to completion at room temperature in from minutes to hours. Suitable reagents include pyridinium chromate and pyridinium chlorochromate. In the second alternative, manganese dioxide is well known to oxidize an allylic hydroxyl, such as found in *trans*-dienylcarbinol AC2, to an aldehyde. This oxidation will proceed at room temperature in an inert organic solvent, such as, toluene, in good yield. Halogenations of the type converting *trans*-dienylcarbinol AC2 to *trans*-diene AC3 wherein Z^a is halomethyl are also well known. Hydroxyalkanes or hydroxyalkenes are well known to react with phosphorus based halogenating agents to produce the corresponding alkyl or alkenylhalide. This reaction will proceed in good yield at room temperature in an inert solvent, such as, a halocarbon, where the phosphorus based halogenating agent is PCl₃, PBr₃ or methyl

triphenoxyphosphonium iodide. *Trans*-diene AC3 wherein Z^a is formyl or halomethyl is conveniently aminated to amine/*trans*-diene AC4. In the case where Z^a is formyl, *trans*-diene AC3 is reacted with R^cNH_2 in the presence of sodium cyanoborohydride and in a solvent, such as, methanol or
5 acetonitrile, to produce *trans*-dienylamine AC4. In the case where Z^a is halomethyl, *trans*-diene AC3 is reacted with excess R^cNH_2 at room temperature in an inert solvent or an alcohol to produce amine/*trans*-diene AC4. Amine/*trans*-diene AC4 is subsequently acylated with *trans*-cinnamoyl chloride or substituted *trans*-cinnamoyl chloride AC5 to form
10 diene/dienophile AC6. This acylation might be carried out in a suitable solvent, such as, THF, with a base, for instance, NaOH, optionally applying heat. Diene/dienophile AC6 may be ring closed in an intramolecular Diels-Alder reaction to give a mixture of bicyclic compounds AC7 and AC8. The intramolecular Diels-Alder reaction is preferably carried out by simply
15 heating diene/dienophile AC6 in a high boiling organic solvent. Suitable high boiling organic solvents boil in a temperature range between 80 and 250 °C and include, for example, toluene, xylene and dichlorobenzene. The reaction might also be carried out with a lower boiling solvent in a pressure apparatus. Preferably the reaction is carried out in a temperature range
20 between 100 and 180 °C under normal pressure. Bicyclic compounds AC7 and AC8 are consecutively hydrogenated and subjected to hydride reduction to produce 4-phenyl(octahydro or hexahydro)-1H-isoindoles 1 and 3, respectively. The hydrogenation may be carried out over Raney nickel or over a noble metal, such as, palladium, platinum, rhodium or nickel, with or
25 without heat and at pressures from atmospheric to 1000 psi. In the case where R^a is nitro, it is preferred that the hydrogenation be carried out over ruthenium. The hydride reduction is carried out with a reducing agent in a suitable organic solvent, such as, THF. Suitable reducing agents include lithium aluminum hydride, sodium diethyl aluminum hydride, borane-methylsulfide and borane-THF. Bicyclic compounds AC7 and AC8 are
30 subjected to hydride reduction to produce the delta-6,7 isoindoles 3 and 1, respectively. In this hydride reduction, suitable reducing agents include lithium aluminum hydride and sodium diethyl aluminum hydride.

FLOW SHEET AC



AD: Synthesis of diastereomers 1 and 2

Diastereomers 1 and 2 of Flow Scheme AD may be obtained from commonly available starting materials which include *trans*-1-phenyl-1,3-butadienes which are 2,3 or 4 R^b substituted, fumaric acid esters and primary amines. Of course, the equivalent *trans*-buta-1,3-dienes with 1-pyridine or 1-thiophene rather than 1-phenyl would be employed in Flow Sheet AD as starting material AD1 to obtain these alternate aryl moieties at the 4-position of the desired octahydro or hexahydro-1H-isoindoles. The description herein using the phenyl bearing *trans*-buta-1,3-diene is for exemplification only. Referring to Flow Sheet AD, in a first reaction step, *trans*-1-phenyl-1,3-butadiene AD1 and fumaric acid ester AD2, a dienophile, are reacted in an intermolecular Diels-Alder reaction to produce diastereomeric diesters AD3 and AD4. The Diels-Alder reaction may be carried out adding the diene AD1 and the dienophile AD2 to an organic solvent and optionally heating or adding a Lewis acid catalyst or pressurizing the reactor. Suitable solvents generally include toluene, xylene, dichlorobenzene, ether, chloromethane, dichloromethane, tetrachloromethane, *n*-hexane, benzene, ethylene glycol or water. Of course, where heat is to be applied, then a high boiling solvent is desirable. Suitable high boiling organic solvents boil in a temperature range between 80 and 250 °C. The reaction might also be carried out with a lower boiling solvent in a pressure apparatus if desired. Suitable Lewis acid catalysts include, aluminum chloride, stannic chloride or boron trifluoride. Preferably the reaction is carried out in a temperature range between room temperature and 180 °C under normal pressure. Subsequently, diesters AD3 and AD4 are consecutively hydrogenated and subjected to hydride reduction to produce diastereomeric diols AD5 and AD6. The hydrogenation may be carried out over Raney nickel or over a noble metal, such as, palladium, platinum, rhodium or nickel, with or without heat and at pressures from atmospheric to 1000 psi. In the case where R^a is nitro, it is preferred that the hydrogenation be carried out over ruthenium. The hydride reduction may be carried out with a reducing agent in a suitable solvent. Suitable reducing agents include lithium aluminum hydride (LAH) and sodium diethylaluminum hydride. Preferred solvents for use with the named reducing agents are the ethereal solvents. Diols AD5 and AD6 are subsequently activated by replacing the hydroxy groups with a leaving group, Z^b, such as, iodide, mesylate (methanesulfonate), tosylate


(p-toluenesulfonate) or trifluoromethanesulfonate, to produce activated diols AD7 and AD8. In a first activating procedure, the hydroxyl moieties may be converted to a methanesulfonate group by treating with methanesulfonyl chloride in the presence of triethylamine. A suitable solvent, e.g.,
5 dichloromethane, is employed and the reaction is carried out at reduced temperatures. In instances where iodide is the desired leaving group, it may be obtained by two procedures, i.e., a second and third activating procedure. In the second procedure, the iodide is obtained from activating methanesulfonyl group, just described, by treatment of the activated
10 compound with sodium iodide in a suitable solvent, e.g., at reduced or ambient temperatures. In the third procedure, the iodide is obtained directly from diols AD5 and AD6 by common methods known to the art. For example, treatment of the hydroxyl group with methyl triphenoxyphosphonium iodide in a suitable solvent, such as
15 dimethylformamide, at reduced or ambient temperatures, directly produces the desired iodide. In a fourth activating procedure, the hydroxyl group may be converted into the reactive trifluoromethanesulfonate (triflate) group. In this procedure, the hydroxyl group is treated with trifluoromethanesulfonic (triflic) anhydride in the presence of a hindered, non-nucleophilic base, such
20 as, 2,6-lutidine, 2,4,6-collidine, or 2,6-di-*t*-butyl-4-methylpyridine, in a suitable solvent, such as, dichloromethane, at reduced temperatures to generate the triflate activating group.

In the final reaction of Flow Sheet AD, activated diols AD7 and AD8 are converted to diastereomers 1 and 2 by reaction with primary amine
25 compound AD9. In general, the conversion is carried out by simply adding the primary amine AD9 to the activated diol AD7 or AD8 in a suitable solvent at reduced temperature or ambient temperature. Suitable solvents include acetonitrile, alcohols, DMF or dichloromethane.

In order to obtain the delta-5,6 isoindoles 1 and 2, the diesters AD3
30 and AD4 are subjected to hydride reduction to produce the unsaturated diols AD5 and AD6. AD5 and AD6 are converted via unsaturated intermediates AD7 and AD8 to the delta-5,6 isoindoles 1 and 2. In this hydride reduction, suitable reducing agents include lithium aluminum hydride and sodium diethyl aluminum hydride. Methodology for conversion of the unsaturated
35 intermediates AD5, AD6, AD7 and AD8 to the final products 1 and 2 is identical to the methodology for preparation of the saturated compounds.

The delta-4,5 isoindoles 1 and 2 are obtained by isomerizing the delta-5,6 isoindoles 1 and 2 with a strongly basic reagent, such as, potassium t-butoxide.

FLOW SHEET AD




2159071

AE: Synthesis of diastereomer 4

Diastereomer 4 of Flow Scheme AE may be obtained from commonly available starting materials which include *trans*-1-phenyl-1,3-butadienes which are 2,3 or 4 R^b substituted and maleimide. Of course, the equivalent *trans*-buta-1,3-dienes with 1-pyridine or 1-thiophene rather than 1-phenyl would be employed in Flow Sheet AE as starting material AE1 to obtain these alternate aryl moieties at the 4-position of the desired octahydro or hexahydro-1H-isoindole. The description herein using the phenyl bearing *trans*-buta-1,3-diene is for exemplification only. Referring to Flow Sheet AE, in a first reaction step, *trans*-1-phenyl-1,3-butadiene AE1 and maleimide AE2, a dienophile, are reacted in an intermolecular Diels-Alder reaction to produce imide AE3. The Diels-Alder reaction may be carried out adding the diene AE1 and the dienophile AE2 to an organic solvent and optionally heating or adding a Lewis acid catalyst or pressurizing the reactor. Suitable solvents generally include toluene, xylene, dichlorobenzene, ether, chloromethane, dichloromethane, tetrachloromethane, η -hexane or benzene. Of course, where heat is to be applied, then a high boiling solvent is desirable. Suitable high boiling organic solvents boil in a temperature range between 80° and 250° C. The reaction might also be carried out with a lower boiling solvent in a pressure apparatus if desired. Suitable Lewis acid catalysts include, aluminum chloride, stannic chloride or boron fluoride. Preferably the reaction is carried out in a temperature range between room temperature and 180 °C under normal pressure. Subsequently, imide AE3 is consecutively hydrogenated and subjected to hydride reduction to produce diastereomeric product 4. The hydrogenation may be carried out over Raney nickel or over a noble metal, such as, palladium, platinum, rhodium or nickel, with or without heat and at pressures from atmospheric to 1000 psi. In the case where R^a is nitro, it is preferred that the hydrogenation be carried out over ruthenium. The hydride reduction may be carried out with a reducing agent in a suitable solvent, such as THF. Suitable reducing agents include lithium aluminum hydride, sodium diethyl aluminum hydride, borane methylsulfide and borane-THF. Bicyclic compound AE3 is subjected to hydride reduction to produce the delta-5,6 isoindoles 4 or mixtures of the delta-5,6 isoindoles and the delta-4,5 isoindoles. In this hydride reduction, suitable reducing agents include lithium aluminum hydride and sodium diethyl aluminum hydride. The delta-5,6 isoindoles may be isomerized with a strongly basic reagent, such as, potassium *t*-butoxide to the delta-4,5 isoindole.

FLOW SHEET AE




As seen, Flow Sheets AA - AD show the production of mixtures of diastereomers. It is assumed herein that persons skilled in the art will be able to separate diastereomers by chromatographic techniques, crystallization techniques or otherwise. Of course, it is clear that the separation may be performed at a point in the reaction scheme following the production of the diastereomeric mixture. Thus, for example, separation of the diastereomers may be performed in Flow Sheet AD at intermediates AD3 and AD4.

Each of the diastereomers, 1-4, has two enantiomers and the synthetic routes shown above produce racemic mixtures of these enantiomers. The individual enantiomers may be separated by use of a chiral auxilliary on nitrogen. This procedure is illustrated in flow sheet AF. The intermediate from flow sheet AD, AD7, is caused to alkylate a chiral α -phenethylamine AE1, such as, (+) or (-)- α -methylphenethylamine, (+) or (-)- α -methyl-*p*-chlorophenethylamine or (+) or (-)- α -1-naphthylethylamine. This alkylation is carried out in a suitable solvent at elevated temperature or ambient temperature with a suitable base, such as, potassium carbonate, sodium bicarbonate or diisopropylethylamine. Suitable solvents include

acetonitrile, alcohols, DMF or dichloromethane. The alkylation produces two diastereomers, AE2 and AE3. These can be separated chromatographically. The α -phenethyl chiral auxiliary on nitrogen is removed by catalytic debenzylolation over a palladium catalyst to give the NH compounds, AE4 and AE5. Alternatively, the chiral auxiliary can be removed by treatment of AE2 and AE3 with a chloroformate reagent, for example, ACE chloride or VOC. The R^c group is then attached to nitrogen either by alkylation or reductive alkylation. In the case of alkylation, an R^cZ reagent is employed where Z is a leaving group as discussed in connection with Flow Sheet AD above. The alkylation is carried out in a suitable solvent at elevated temperature or ambient temperature with a suitable base, such as, potassium carbonate, sodium bicarbonate or diisopropylethylamine. Suitable solvents include acetonitrile, alcohols, DMF or dichloromethane. In the case of reductive alkylation, AE4 and AE5 are reacted with a carbonyl compound and a hydrogen source. The hydrogen source may include hydrogen over a palladium or platinum catalyst or NaBH₃CN or formic acid at elevated temperatures. Where the carbonyl compound is formaldehyde, then R^c is methyl; acetaldehyde, then R^c is ethyl; benzaldehyde, then R^c is benzyl; and acetone, then R^c is isopropyl.

FLOW SHEET AF



If in the operation of Flow Sheets AA through AE, at the stage of introduction of R^C , a chiral auxiliary is similarly employed, diastereomers will be produced which can be, in like manner, converted to the desired enantiomers. Alternatively, by classical resolution techniques diastereomers 1 through 4 can be reacted with chiral acids, such as, (+) or (-) ditoluoyltartaric acid, (+) or (-) camphorsulfonic acid or (+) or (-) ditolytartaric acid. Separation of the resultant diastereomeric mixture and subsequent reconversion to the base will produce the desired enantiomers.

As stated, the manufacture of starting materials described above is well known. *Trans*-cinnamoyl chloride starting materials AA3, AB2 and AC5, as well as the thienyl and pyridyl equivalents, may be produced by either of two condensation reactions. In a Knoevenagel Condensation reaction, an optionally substituted arylaldehyde is reacted with malonic acid, $\text{CH}_2(\text{COOH})_2$, in the presence of pyridine to produce a *trans*- β -arylacrylic acid. In a Perkin Condensation reaction, an optionally substituted arylaldehyde is reacted with acetate, CH_3COO^- , in the presence of acetic anhydride to produce the *trans*- β -arylacrylic acid. The *trans*-cinnamoyl chloride may be prepared from the *trans*-cinnamic acid by heating with a halogenating reagent, such as: thionyl chloride, oxalyl chloride or phosphoryl chloride. The starting materials AD1 and AE1, 1-aryl-*trans*-buta-1,3-dienes, which are 2,3 or 4 R^b substituted or optionally R^a substituted, may be produced in a Wittig reaction. In the Wittig reaction, optionally substituted allyltriphenylphosphonium halide is reacted with optionally substituted arylaldehyde in the presence of a base and in a suitable solvent at from -50 °C to room temperature. Effective bases include potassium *t*-butoxide, *n*-butyl lithium and sodium hexamethyldisilazide and useful solvents are inert solvents such as THF. The starting material AE2 may be obtained by adding the primary amine, $R^C\text{NH}_2$, to maleic anhydride at room to elevated temperature and condensing the resultant product in situ either by simply heating to about 150 °C or by the addition of a condensing agent such as acetic anhydride or thionyl chloride.

As stated, the objective of the second synthetic stage is to substitute the core 4-phenyl(octahydro or hexahydro)-1H-isoindole with desired R^a , R^b , and R^C . In the case of R^C , the desired substituents may be obtained from appropriately substituted starting materials. Specifically, in Flow Sheet AA, starting compound AA1 is appropriately substituted with desired R^C . Likewise, in Flow Sheets AB, AC, AD and AE, starting compounds AB1,

AC4, AD9 and AE2, consecutively, are appropriately substituted. Alternatively, diverse R^c may be obtained from a benzyl precursor substituent. The benzyl group on nitrogen is removed by catalytic debenzylation over a palladium catalyst to give the NH compound.

- 5 Alternatively, the benzyl group can be removed by treatment with a chloroformate reagent, for example, ACE chloride or VOC. The R^c group is then attached to nitrogen either by alkylation or reductive alkylation. In the case of alkylation, an R^cZ reagent is employed where Z is a leaving group as discussed in connection with Flow Sheet AD above. The alkylation is
- 10 carried out in a suitable solvent at elevated temperature or ambient temperature with a suitable base, such as: potassium carbonate, sodium bicarbonate or diisopropylethylamine. Suitable solvents include acetonitrile, alcohols, DMF or dichloromethane. In the case of reductive alkylation the NH compound is reacted with a carbonyl compound and a hydrogen source.
- 15 The hydrogen source may include hydrogen over a palladium or platinum catalyst or $NaBH_3CN$ or formic acid at elevated temperatures. Where the carbonyl compound is formaldehyde, then R^c is methyl; acetaldehyde, then R^c is ethyl; benzaldehyde, then R^c is benzyl; and acetone, then R^c is isopropyl.

- 20 In the case of R^b , the desired substituents may be obtained from the appropriately substituted starting materials. Again, specifically, in Flow Sheet AA, starting compound AA1 is appropriately substituted with desired R^b . In Flow Sheets AB, AC, AD and AE, starting compounds AB5, AC1, AD1 and AE1 are appropriately substituted. Of course, it is clear in the case of
- 25 both R^c and R^b that obtaining these desired substituents involves the use of conventional chemistry with relatively well known reactants.

- In the case of R^a , there is greater variation in both the substituent itself and the substrate to which it is attached and, thus, further description is necessary. The pyridine and thiophene equivalents to *trans*-cinnamoyl
- 30 chloride, compounds AA3, AB2 and AC5, or 1-pyridyl-*trans*-buta-1,3-diene, equivalent to compounds AD1 or AE1, or 1-thienyl-*trans*-buta-1,3-diene equivalent to compounds AD1 or AE1, are R^{a2} substituted where R^{a2} is halogen or C_{1-4} alkyl. Each of the R^{a2} substituents may be synthesized on the thienyl or pyridyl starting material and carried through the synthesis of
- 35 Flow Sheets AA, AB, AC, AD and AE. As described above, the synthesis of this starting material would require only the synthesis of R^{a2} substituted pyridyl or thienyl aldehyde and the use of this aldehyde in a Knoevenagel

2159071

Condensation, a Perkin Condensation or a Wittig Reaction. The *trans*-cinnamoyl chloride, compounds AA3, AB2 and AC5, or *trans*-1-phenyl-1,3-butadiene, compounds AD1 or AE1, are R^{a1} substituted where R^{a1} is hydroxy, halogen, C₁-4alkyl, substituted C₁-4alkyl (wherein the substituent is C₁-4alkoxy, hydroxy or perhalo), C₁-4alkoxy, substituted C₁-4alkoxy (wherein the substituent is perfluoro), C₁-4alkylthio, cyano, nitro, amino, C₁-4alkylamino, diC₁-4alkylamino, C₁-4alkylsulfonyl, C₁-4alkylsulfinyl, phenyl, phenylthio, C₁-4acylamino, carboxy, C₁-4acyl and benzoyl.

The majority of the R^{a1} substituents may simply be synthesized on the *trans*-cinnamoyl chloride or the *trans*-1-phenyl-1,3-butadiene and carried through the synthesis of Flow Sheets AA, AB, AC, AD or AE. As described above, the synthesis of these starting materials would require only the synthesis of R^{a1} substituted benzaldehyde and the use of this aldehyde in a Knoevenagel Condensation, a Perkin Condensation or a Wittig Reaction. R^{a1} substituents which may be obtained in this manner are halogen, C₁-4alkyl, substituted C₁-4alkyl (wherein the substituent is C₁-4alkoxy or perhalo), C₁-4alkoxy, substituted C₁-4alkoxy (wherein the substituent is perfluoro), C₁-4alkylthio, nitro, diC₁-4alkylamino, phenyl, phenylthio, C₁-4acyl and benzoyl. In the case of hydroxy or C₁-4alkyl substituted with hydroxy, these R^{a1} substituents may be obtained by protecting the hydroxy with methyl or benzyl and, on the octahydro or hexahydro-1H-isoindole, cleaving the protecting group with BBr₃ in a halocarbon solvent at reduced temperature or with HBr or HI in water at elevated temperatures. In the case of cyano, this R^{a1} substituent may be obtained by employing Br as a precursor substituent on the octahydro or hexahydro-1H-isoindole. The bromine precursor substituent is replaced with cyano by treatment with sodium cyanide or cuprous cyanide in an inert solvent at elevated temperatures over a Pd(0) catalyst. In the case of the C₁-4alkylsulfonyl, these substituents may be obtained by oxidizing a C₁-4alkylthio precursor substituent on octahydro or hexahydro-1H-isoindole using hydrogen peroxide in acetic acid, potassium permanganate in water, nitric acid, sodium perborate or meta-chloroperbenzoic acid in halocarbon. In the case of the C₁-4alkylsulfinyl, these substituents may be obtained by oxidizing a C₁-4alkylthio precursor substituent on octahydro or hexahydro-1H-isoindole using sodium periodate in water or meta-chloroperbenzoic acid in a halocarbon solvent. In the case of amino, this substituent may be obtained by catalytic reduction of NO₂ and the alkylamino obtained from the

amino by acylation, followed by hydride reduction. In the case of C₁₋₄acylamino, these substituents may be obtained by treating an amino precursor substituent on octahydro or hexahydro-1H-isoindole with a C₁₋₄carboxylic acid or anhydride. In the case of carboxy, this substituent
5 may be obtained by hydrolyzing a cyano precursor substituent on octahydro or hexahydro-1H-isoindole to carboxamido using polyphosphoric acid at elevated temperatures or by partial saponification with sodium hydroxide, followed by hydrolyzing further with sodium hydroxide.

Preferred R^{a1} are selected from the group consisting of hydroxy,
10 bromine, chlorine, fluorine, methyl, ethyl, n-propyl, i-propyl, t-butyl, methoxymethyl, ethoxyethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, trifluoromethyl, trichloromethyl, methoxy, ethoxy, t-butoxy, trifluoromethoxy, methylthio, ethylthio, n-propylthio, cyano, nitro, amino, methylamino, ethylamino, n-propylamino, dimethylamino, diethylamino, methylethylamino,
15 methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, methylsulfinyl, ethylsulfinyl, n-propylsulfinyl, phenyl, phenylthio, formylamido, acetamido, propionylamido, carboxy, formyl, acetyl, propionyl and benzoyl;


Preferred R^{a2} are selected from the group consisting of bromine, chlorine, fluorine, methyl, ethyl, n-propyl, i-propyl or t-butyl.

20 Preferred R^b are selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, i-propyl and t-butyl.

Preferred R^c are selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, i-propyl, t-butyl, benzyl, diphenylmethyl, dimethylaminomethyl, dimethylaminoethyl, dimethylaminopropyl,
25 diethylaminomethyl, diethylaminoethyl, allyl, benzyl, cyclopropylmethyl, cyclopropyl and cyclohexyl.

2159071

Preferred compounds of Formula (I) above, include:




wherein R^a , R^b and R^c are simultaneously selected from the group consisting of the groups:

5	R^a	R^b	R^c
	4'-F	5-Me	Me,
	3'-methoxy	H	Me,
	3'-methoxy	H	H,
	3'-CF ₃	H	Me,
10	3'-methoxy	H	benzyl,
	2',3'-dimethoxy	H	Me,
	3',4'-dichloro	H	Me,
	3'-OH	H	Me,
	-	H	Me,
15	4'-CF ₃	H	Me,
	3'-CF ₃	H	n-butyl,
	4'-NO ₂	H	Me,
	4'-NH ₂	H	Me,
	4'-NHCOCH ₃	H	Me,
20	4'-Cl	H	Me,
	2'-Cl	H	Me,
	2',5'-dichloro	H	Me,
	4'-F	H	Me,
	4'-methoxy	H	Me,
25	3',4'-dimethoxy	H	Me,
	4'-i-propyl	H	Me,
	4'-CN	H	Me,













4'-Br	H	Me,
4'-SMe	H	Me,
4'-SO ₂ Me	H	Me, and
3'-methoxy	H	benzyl,

5 including the stereoisomers thereof.


The most preferred compounds of Formula I are:




2159071




2159071



2159071





The activity of compounds of the invention as analgesics may be demonstrated by the mouse acetylcholine-bromide induced constriction assay as described below:

Mouse Acetylcholine Bromide-Induced Abdominal Constriction Assay

The mouse acetylcholine-induced abdominal constiction assay, as described by Collier et al. in *Brit. J. Pharmacol. Chem. Ther.*, 32: 295-310, 1968, with minor modifications was used to assess analgesic potency of the compounds of formula (I). The test drugs or appropriate vehicle were administered orally (p.o.) and 30 minutes later the animal received an intraperitoneal (i.p.) injection of 5.5 mg/kg acetylcholine bromide (Matheson, Coleman and Bell, East Rutherford, NJ). The mice were then placed in

2159071

groups of three into glass bell jars and observed for a ten minute observation period for the occurrence of an abdominal constriction response (defined as a wave of constriction and elongation passing caudally along the abdominal wall, accompanied by a twisting of the trunk and followed by extension of the hind limbs). The percent inhibition of this response to a nociceptive stimulus (equated to % analgesia) was calculated as follows: The % Inhibition of response, i.e., % analgesia is equal to the difference between the No. of control animals response and the No. of drug-treated animals response times 100 divided by the No. of control animals responding.

At least 15 animals were used for control and in each of the drug treated groups. At least three doses were used to determine each dose response curve and ED₅₀ (that dose which would produce 50% analgesia). The ED₅₀ values and their 95% fiducial limits were determined by a computer assisted probit analysis.

TABLE I
Mouse Acetylcholine-Bromide Induced
Abdominal Constriction Assay

	<u>Compound Number</u>	<u>% Inhibition</u>	<u>ED₅₀</u>
20	Cp-1	30-40% @30 mpk/po	
	Cp-2		47.6 mpk/po
	Cp-3		22.1 mpk/po
	Cp-4	60% @30 mpk/po	
	Cp-5		5.5 mpk/po
25	Cp-6	13.3% @30 mpk/po	
	Cp-7		7.46 mpk/po
	Cp-8	78.8% @30 mpk/po	
	Cp-9		3.8 mpk/po
	Cp-10		30 mpk/sc
30	Cp-11		3 mpk/po
	Cp-12		6.26 mpk/po
	Cp-13		8.35 mpk/po
	Cp-14		2.8 mpk/po
	Cp-15		7.0 mpk/po
35	Cp-16		4.6 mpk/po

	Cp-17	33% @ 3 mpk/po	
	Cp-18	66.7% @ 30 mpk/po	
	Cp-19		5.3 mpk/po
	Cp-20		5.4 mpk/po
5	Cp-21	100% @ 30 mpk/po	
	Cp-22	13.3% @ 30 mpk/po	
	Cp-24		23.6 mpk/po
	Cp-24+		21.6 mpk/po
	Cp-24-		24.9 mpk/po
10	Cp-25	67% @ 30 mpk/po	
	Cp-28	0% @ 30 mpk/po	
	Cp-31	20% @ 30 mpk/po	
	Cp-32		1.36 mpk/po
	Cp-33		10.5 mpk/po
15	Cp-34	100% @ 30 mpk/po	
	Cp-35		9.63 mpk/po
	Cp-37		2.0 mpk/po
	Cp-38		9.88 mpk/po
	Cp-39		1.79 mpk/po
20	Cp-40	100% @ 30 mpk/po	
	Cp-41		2.5 mpk/po
	Cp-42	100% @ 30 mpk/po	
	Cp-43		4.9 mpk/po
	Cp-44		9.15 mpk/po
25	Cp-45	33% @ 30 mpk/po	
	Cp-46	100% @ 30 mpk/po	
	Cp-47		4.0 mpk/po
	Cp-48		3.8 mpk/po
	Cp-49		4.3 mpk/po
30	Cp-50		4.07 mpk/po
	Cp-51		15.6 mpk/po
	Cp-52		12.1 mpk/po
	Cp-53		10.1 mpk/po

Based on the above results, invention compounds of formula (I) may
35 be used to treat mild to moderately severe pain in warm-blooded animals
such as humans in a manner similar to the use of meperidine hydrochloride
by administration of an analgesically effective dose. The dosage range
would be from about 10 to 3000 mg, in particular about 25 to 1000 mg or

about 100 or 500 mg, of active ingredient 1 to 4 times per day for an average (70 kg) human although it is apparent that activity of individual compounds of the invention will vary as will the pain being treated. Pharmaceutical compositions of the invention comprise the formula (I) compounds as
5 defined above, particularly in admixture with a pharmaceutically-acceptable carrier.


To prepare the pharmaceutical compositions of this invention, one or more compounds of formula (I) or salt thereof of the invention as the active ingredient, is intimately admixed with a pharmaceutical carrier according to
10 conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration, e.g., oral or parenteral such as intra muscular. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Thus, for liquid oral preparations, such as for
15 example, suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like; for solid oral preparations such as, for example, powders, capsules and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders,
20 disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. For parenterals, the carrier will usually comprise sterile water,
25 through other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful
30 and the like, an amount of the active ingredient necessary to deliver an effective dose as described above.

The pharmaceutically acceptable salts referred to above generally take a form in which the nitrogen of the core ring and/or possibly a nitrogen of a substituent is protonated with an inorganic or organic acid.
35 Representative organic or inorganic acids include hydrochloric, hydrobromic, hydroiodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric,


benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, *p*-toluenesulfonic, cyclohexanesulfamic, salicylic or saccharic.

The following Examples illustrate the invention:

PROCEDURE A





Pyridinium methiodide (22 g, 0.1 mol) was added to a suspension of lithium
5 aluminum hydride (5.6 g, 0.15 mol) and tetrahydrofuran (400 mL). This
mixture was heated at reflux for 16 h and cooled to room temperature.
Successive portions of water (5.6 mL), 3N NaOH (16.8 mL) and water (5.6
mL) were added to the cooled mixture. The precipitate was filtered and
washed with THF. The filtrate containing compound A, was dissolved in
10 THF (1 L) and used without further purification (M. Fereles, *et al. Coll.*
Czech Chem Comm, 1973, 38, 615-619).



m-Trifluoromethylcinnamoyl chloride (16.4 g, 69 mmol) was added to
15 a stirred solution of 3N NaOH (50 mL, 150 mmol), ice/water (10 mL) and *N*-
methyl-*N*-(2,4-pentadien-1-yl)amine/THF (ca. 50 mmol) and this mixture was
stirred for 15 min. Ether was added to the resulting mixture and the aqueous
layer was removed. The organic layer was washed with successive portions
of aqueous dimethylaminopropylamine solution, dilute HCl, and brine; dried
20 (MgSO₄), filtered, and concentrated *in vacuo*. The residue was purified by
column chromatography on silica gel using acetone/hexane (15/85) as an
eluent to give compound B, as an oil which crystallized upon standing.

¹H NMR (CDCl₃, 300 MHz): δ 7.9-7.4 (m, 4H), 6.9-6.7 (m, 2H), 6.3 (t, 1H),
5.5-5.2 (m, 3H), 4.4-4.3 (doubled dd, 2H), 3.2-3.1 (doubled s, 3H).



A solution of the amide **B** (4.6 g, 15.57 mmol) in toluene was heated at reflux for 16 h and concentrated in vacuo. The resulting mixture was separated by column chromatography (Waters Prep 500 : acetone/hexane, 20/80 as eluent) and the isolated components were recrystallized from hexane to give diastereomers **C** and **D**.

Compound C


¹H NMR (CDCl₃, 300 MHz): δ 7.5-7.4 (m, 4H), 5.9 (d, 1H), 5.65 (m, 1H), 3.3 (m, 1H), 3.2 (m, 1H), 2.8 (s, 3H), 2.9-2.75 (m, 1H), 2.6 (m, 2H), 2.2 (m, 1H).

Anal. Calc'd for C₁₆H₁₆F₃NO: C, 65.07; H, 5.46; N, 4.74
Found: C, 65.23; H, 5.32; N, 4.67

Compound D

¹H NMR (CDCl₃, 300 MHz): δ 7.55 (s, 1H), 7.5-7.3 (m, 3H), 6.0 (m, 1H), 5.65 (d, 1H), 3.6 (m, 1H), 3.5 (m, 1H), 3.07 (d, 1H), 2.87 (s, 3H), 2.77 (s, 2H), 2.5 (m, 1H), 2.2 (m, 1H).

Anal. Calc'd for C₁₆H₁₆F₃NO: C, 65.07; H, 5.46; N, 4.74
Found: C, 65.05; H, 5.31; N, 4.65.




10 % Pd/C (45 mg) was added to a solution of compound C (0.45 g, 1.5 mmol) in EtOH (20 mL) and the resulting mixture was pressurized with H₂ (35 psi) for 16 h. The mixture was filtered and concentrated in vacuo to give compound E, as an oil which was used without further purification.

- 5 ¹H NMR (CDCl₃, 300 MHz): δ 7.5-7.4 (m, 4H), 6.0 (m, 1H), 3.25 (m, 1H), 3.1 (t, 1H), 2.75 (s, 3H), 2.8-2.7 (m, 1H), 2.2 (m, 1H), 2.0 (m, 4H), 1.5-1.3 (m, 4H).

Anal. Calc'd for C₁₆H₁₈F₃NO: C, 64.63; H, 6.10; N, 4.71
Found: C, 64.26; H, 6.02; N, 4.67

10

EXAMPLE 1Cp-7

3α, 4α, 7αβ-Octahydro-2-methyl-4-(3-trifluoromethylphenyl)-
1H-isoindole Monofumarate


- 15 1 M Borane/THF complex (4 mL, 4 mmol) was added to a solution of compound E (0.4 g, 1.3 mmol) in THF (5 mL). This mixture was heated at reflux for 16 h under Ar and cooled to room temperature. A portion of water (25 mL) was added and the organic solvent was removed in vacuo. Propionic acid (3 mL) was added and the resulting mixture was heated on a
- 20 steam bath for 4 h, poured into aqueous NaOH and extracted with methylene chloride. The combined organic extracts were dried (K₂CO₃), concentrated in vacuo and combined with fumaric acid (0.15 g). This mixture was dissolved in hot isopropanol and a portion of ether was added. The resulting precipitate was isolated from the solution to give the title
- 25 compound as a solid: mp 152-154 °C.

¹H NMR (DMSO d₆, 300 MHz): δ 7.6 (m, 4H), 6.47 (s, 2H), 3.34 (m, 1H),

2.9-2.65 (m, 4H), 2.64 (s, 3H), 2.1 (m, 1H), 1.95-1.75 (m, 4H), 1.5 (m, 2H), 1.2 (m, 1H)

Anal. Calc'd for $C_{16}H_{20}F_3N \cdot C_4H_4O_4$: C, 60.14; H, 6.06; N, 3.51
Found: C, 60.09; H, 6.04; N, 3.43

5


PROCEDURE B

10% Pd/C (0.24 g) was added to a solution of compound **D** (2.40 g, 8.07 mmol) in EtOH (50 mL) and the resulting mixture was pressurized with H_2 (50 psi) for 1 h. The mixture was filtered and concentrated in vacuo to give compound **F** as an oil which crystallized upon standing.

^1H NMR ($CDCl_3$, 300 MHz): δ 7.5 (s, 1H), 7.45 (m, 3H), 3.45 (m, 1H), 3.3 (dd, 1H), 3.05 (dd, 1H), 2.9 (bs, 3H), 1.9-1.63 (m, 3H), 1.4 (m, 3H).

Anal. Calc'd for $C_{16}H_{18}F_3NO$: C, 64.63; H, 6.10; N, 4.71
Found: C, 64.91; H, 6.02; N, 4.66

15

EXAMPLE 2

3 α , 4 α , 7 α -Octahydro-2-methyl-4-(3-trifluoromethylphenyl)-
1H-isoindole Monofumarate

20

1 M Borane/THF complex (21 mL, 21 mmol) was added to a solution of compound F (2.1 g, 7.1 mmol) in THF (20 mL) and this mixture was heated to reflux for 16 h under Ar and cooled to room temperature. A portion of water (1.4 mL) was added and the organic solvent was removed in vacuo.

5 Propionic acid (5.6 mL) was added and the resulting mixture was heated on a steam bath for 3 h, poured into dilute aqueous NaOH and extracted with ether. The organic layer was washed with dilute HCl and the resulting aqueous layer was made basic with NaOH and extracted with methylene chloride. The combined organic extracts were dried (K₂CO₃), concentrated
10 in vacuo and combined with fumaric acid (0.51 g). This mixture was dissolved in isopropanol and the resulting precipitate was isolated from the solution to give the title compound as a solid: mp 152-154 °C.

¹H NMR (DMSO d₆, 300 MHz): δ 7.65-7.5 (m, 4H), 6.5 (s, 2H), 3.37 (t, 1H),
3.05 (t, 1H), 2.9-2.7 (m, 3H), 2.63 (s, 3H), 2.4 (m, 4H), 1.5 (m, 1H),
15 1.72-1.43 (m, 6H).

Anal. Calc'd for C₁₆H₂₀F₃N•C₄H₄O₄: C, 60.14; H, 6.06; N, 3.51
Found: C, 60.25; H, 5.98; N, 3.42

PROCEDURE C

The following general procedure was used to synthesize the compounds
20 listed in Table 1.

An appropriately substituted cinnamoyl chloride derivative (10.0 mmol) was added to a stirred solution of 3N NaOH (21.74 mmol), ice/water (1.4 mL) and *N*-methyl-*N*-(2,4-pentadien-1-yl) amine/THF (ca. 7.25 mmol) and this mixture was stirred for 15-30 min. A suitable organic solvent such as ether
25 was added to the resulting mixture and the aqueous layer was removed. The organic layer was washed with successive portions of an *N,N*-dialkylaminoalkylamine solution such as dimethylaminopropylamine solution, an acidic solution such as HCl and brine; dried (MgSO₄), filtered, and concentrated in vacuo. The residue was purified using any of the
30 standard techniques which include column chromatography and recrystallization to give the coupled amide derivative **AA4**.


A solution of the amide derivative **AA4** (10.0 mmol) in a suitable organic solvent such as toluene was heated at reflux for 16-36 h and concentrated in vacuo. The resulting residue was purified by any of the standard

methods which include column chromatography and recrystallization to give the cyclized derivatives **AA5** and **AA6**.

A catalytic portion of 10 % Pd/C was added to a solution of an appropriately substituted derivative **AA6** (10.0 mmol) in a suitable solvent such as EtOH (132 mL) and the resulting mixture was pressurized with H₂ (at approximately 35 psi) for 16 h. The mixture was filtered and concentrated in vacuo to give the saturated derivative, which was used without further purification.

1 M Borane/THF complex (29.0 mmol) was added to a solution of the saturated derivative (10.0 mmol) in THF (28 mL). This mixture was heated to reflux for 16 h under Ar and cooled. A portion of water (1.97 mL) was added and the organic solvent was removed in vacuo. Propionic acid (7.88 mL) was added and the resulting mixture was heated on a steam bath for 3 h, poured into NaOH aq. and extracted with a suitable organic solvent such as ether. The organic layer was washed with HCl aq. and the resulting aqueous layer was made basic with NaOH and extracted with a suitable organic solvent. The combined organic extracts were dried and concentrated in vacuo. The residue was dissolved in a suitable solvent, treated with an appropriate organic or mineral acid and crystallized from this mixture to give the desired derivative **3**.


Table 1



Cp-n	(R ^a) _n	R ^c	mp °C	C	H	N	Empirical Formula	MS (MH [±])
Cp-1	3-OMe	Me	111-3	66.30	7.43	3.81	C ₁₆ H ₂₃ NO•C ₄ H ₄ O ₄	246
Cp-8	2,3-di-OMe	Me	154-6	62.24	7.55	3.78	C ₁₇ H ₂₅ NO ₂ •C ₂ H ₂ O ₄	276
Cp-9	3,4-di-Cl	Me	176-8	57.46	5.95	3.45	C ₁₆ H ₂₃ NO•C ₄ H ₄ O ₄ • 1/8 C ₂ H ₈ O	285


2159071

PROCEDURE D




G

Allyltriphenylphosphonium bromide (300 g, 0.78 mol) was added
5 portionwise under Ar to a cooled solution of sodium bis(trimethylsilyl)amide
(1.0 mol/THF: 776 mL, 0.78 mol) and THF (1 L). The resulting mixture was
stirred for another 30 min and a solution of 3-methoxybenzaldehyde (97 g,
0.71 mol) in THF was added to the mixture over 1.5 h. The reaction mixture
was stirred for 2 h and poured into ice/water. The organic layer was
10 removed and the resulting aqueous layer was washed with several portions
of ether. The combined organic layers were washed with brine, dried
(MgSO₄) and concentrated in vacuo. The residue was dissolved in
t-butylmethylether and the resulting precipitate (triphenylphosphine oxide)
was removed by filtration. The filtrate was treated in the same manner
15 several times until most of the triphenylphosphine oxide was removed. The
resulting residue was purified by column chromatography on silica gel
using hexane/acetone, (10/1) as an eluent to give the diene G, as an oil.



H


20 A suspension of diene G (50 g, 0.31 mol), N-methylmaleimide (35 g, 0.31
mol) and water (500 mL) was stirred in a Morton flask for 16 h under Ar and
extracted with methylene chloride. The combined organic extracts were
washed with brine, dried (MgSO₄) and concentrated in vacuo. The residue
was purified by column chromatography using hexane/acetone (5/1) as an
25 eluent to give the coupled product H as an oil: MS 271.



A suspension of the coupled product H (17.0 g, 62.7 mmol), 10% Pd/C (1.7 g) and ethyl acetate (200 mL) was placed in a Parr bottle and pressurized with H₂ for 3 h. The catalyst was filtered and the filtrate was concentrated in vacuo to give the saturated product I as an oil.

¹H NMR (CDCl₃, 300 MHz): δ 7.5 (t, 1H), 6.9-6.8 (m, 3H), 3.8 (s, 3H), 3.3 (m, 1H), 3.1-3.0 (m, 2H), 2.9 (s, 3H), 2.15 (m, 1H), 1.95 (m, 1H), 1.8-1.5 (m, 4H).

EXAMPLE 3




3α, 4β, 7α-Octahydro-1-methyl-4-(3-methoxyphenyl)-1H-isoindole Monooxalate 0.2 Hydrate

1 M Borane/THF (180 mL, 0.18 mol) was added dropwise to a solution of the saturated product I (8 g, 29 mmol) in THF (85 mL) and the reaction mixture was heated to reflux for 16 h. Propionic acid (561 mL, 7.52 mol) was added and the resulting mixture was heated at reflux for another 3 h. The resulting mixture was cooled to room temperature, basified with NaOH and extracted with several portions of ether. The combined organic extracts were washed with water followed by brine, dried (K₂CO₃) and concentrated in vacuo. The residue was treated with another portion of propionic acid (300 mL, 4 mol) at reflux for 8 h followed by the standard work-up described above. The resulting residue was purified by column chromatography on

silica gel using methylene chloride/methanol/ammonium hydroxide (90/10/1) as an eluent to give the free base of the title compound as an oil. Treatment of this base with oxalic acid followed by recrystallization with isopropanol gives the title compound as a solid: mp 121-124 °C.

5 Anal. Calc'd for C₁₆H₂₃NO•C₂H₂O₄•0.2 H₂O: C, 63.77; H, 7.55; N, 4.31
 Found: C, 63.84; H, 7.57; N, 4.12

EXAMPLE 4





Cp-10

10 3α, 4α, 7aβ-Octahydro-2-methyl-4-(3-hydroxyphenyl)
-1H-isoindole Hemifumarate

A mixture of 3a α , 4 α , 7a β -octahydro-2-methyl-4-(3-methoxyphenyl)-1H-isoindole (2.0 g, 8.1 mmol) and 48% HBr (40 mL) was heated at reflux for 4 h and concentrated in vacuo. The residue was washed with ether, dissolved in isopropanol, treated with enough ether to cloud the clear solution and placed in the freezer for 16 h. The resulting suspension was concentrated in vacuo and partitioned between NaHCO₃ aq. and methylene chloride. The organic layer was concentrated in vacuo and the resulting residue was treated with fumaric acid, isopropanol and ether. The title compound was isolated from this mixture as a tan solid: mp 224 °C dec, Exact Mass: Calc'd 231.16231 Found 231.1664.

PROCEDURE E




A mixture of *cis*-diene **G** (17.4 g, 0.11 mol), fumaronitrile (8.3 g, 0.11 mol),
5 hydroquinone (0.1 g) and toluene was heated in a closed system at 125 °C
for 16 h and concentrated in vacuo. The residue was recrystallized from
hexane/ethyl acetate and the first crop of crystals was recrystallized from
the same solvent mixture to give compound **K** as a solid: mp 133-135 °C.
The first mother liquor was concentrated in vacuo and purified by a
10 combination of bulb to bulb distillation (at 100 °C and 0.001 mm Hg) and
successive recrystallizations from ethyl acetate/hexane to give compound **J**
as a solid: mp 96-99 °C.

Compound **J**:

¹H NMR (CDCl₃, 300 MHz): δ 7.37-7.27 (m, 1H), 6.95-6.85 (m, 3H),
15 6.0 (m, 1H), 6.1 (m, 1H), 3.85 (s, 3H), 3.4 (t, 1H), 3.3 (q, 1H),
2.9-2.8 (m, 1H), 2.65 (m, 1H).

Compound **K**:

¹H NMR (CDCl₃, 300 MHz): δ 7.3 (m, 1H), 6.85 (m, 3H), 5.9 (m, 1H),
5.7 (m, 1H), 3.8 (m, 1H), 3.6 (m, 1H), 3.2 (m, 1H), 2.9 (t, 1H),
20 2.7-2.65 (t, 1H), 2.65 (m, 1H).




A mixture of compound **K** (20.0 g, 0.08 mol), 10% Pd/C (2.0 g) and ethyl
acetate (200 mL) was placed in a Parr bottle and pressurized for 4 h under

2159071


H₂. The catalyst was filtered and the mother liquor was concentrated in vacuo. The residue was purified by a combination of techniques which include recrystallization from methylcyclohexane/ethyl acetate and column chromatography on silica gel using hexane/acetone (5/1) to give the saturated compound L as a solid: mp 80-82 °C.

Anal. Calc'd for C₁₅H₁₆N₂O: C, 74.97; H, 6.71; N, 11.66
Found: C, 75.16; H, 6.60; N, 11.42

**M**

10 A mixture of the saturated compound L (5.0 g, 20.8 mmol), water (20 mL), 85% H₃PO₄ and glyme (5 mL) was heated at reflux for 50 h and stirred at room temperature for 72 h. The resulting mixture was poured into ice/water and extracted with ether/THF. The combined organic layers were washed with water, and brine, dried (MgSO₄) and concentrated in vacuo. The
15 residue was purified by recrystallization from methylcyclohexane/ethyl acetate (96/2) to give the saturated diacid M as a solid: mp 194-196 °C.

Anal. Calc'd for C₁₅H₁₈O₅: C, 64.74; H, 6.52
Found: C, 64.61; H, 6.58

**N**


20 1.0 M Borane/THF (231 mL, 0.231 mol) was added dropwise to a solution of the diacid M (12.4 g, 44.6 mmol) in THF (80 mL) and the resulting mixture was stirred for 16 h at room temperature under Ar. Water (170 mL) was added to the reaction mixture followed by several washes with ether. The

combined organic extracts were washed with water and brine, dried (MgSO₄) and concentrated in vacuo. The residue was dissolved in THF (120 mL), another portion of 1.0 M Borane/THF (115 mL, 0.115 mol) was added and the reaction was stirred at room temperature for another 16 h.

- 5 The resulting mixture was worked-up as previously mentioned, and recrystallized from methylcyclohexane/ethyl acetate to give the diol intermediate N as a solid: mp 97-98 °C.

Anal. Calc'd for C₁₆H₂₃NO•C₂H₂O₄•0.2 H₂O: C, 71.97; H, 8.86
Found: C, 71.94; H, 8.89

10

EXAMPLE 5Cp-2


3α, 4α, 7αβ-Octahydro-2-methyl-4-(3-methoxyphenyl)
-1H-isoindole Monofumarate 0.1 Hydrate

- 15 A solution of methanesulfonyl chloride (6.1 mL, 0.08 mol) in methylene chloride (6 mL) was added dropwise to a solution of the diol intermediate N (5 g, 0.02 mol) and triethylamine (13 mL, 0.1 mol) in methylene chloride at 0 °C and stirred for 2.5 h. The reaction mixture was poured into aqueous NaHCO₃ and the organic layer was extracted with brine, dried (MgSO₄)
- 20 and concentrated in vacuo. The resulting residue and KI (7.3 g, 0.44 mol) were dissolved in DMF (60 mL), heated to 60 °C for 2 h, cooled to room temperature and transferred to a pressure bottle. Monomethylamine (g) was bubbled into the vessel over 5 min and the resulting mixture was heated at 60 °C for 16 h. This mixture was poured into water and extracted
- 25 with ethyl acetate. The combined organic extracts were washed with water and brine, dried (K₂CO₃) and concentrated in vacuo. The residue was dissolved in ether/isopropanol and the precipitate was removed by filtration. The filtrate was concentrated in vacuo, and purified by chromatography (Waters Prep 500:silica gel, methylene chloride/methanol (90/10) to


methylene chloride/methanol:ammonium hydroxide (90/9.5/0.5)) and crystallization from fumaric acid and isopropanol/EtOH to give the title compound as a solid: mp 182-189 °C.

Anal. Calc'd for $C_{16}H_{23}NO \cdot C_4H_4O_4 \cdot 0.1 H_2O$: C, 66.13; H, 7.55; N, 3.86
Found: C, 65.98; H, 7.66; N, 3.81

PROCEDURE F



A mixture of 1-(3-trifluoromethylphenyl)-1,3-butadiene (10 g, 0.05 mol), dimethyl fumarate (7.2 g, 0.05 mol) and ethylene glycol was heated at 60 °C for 16 h. The reaction mixture was poured into water and extracted with ether. The combined organic extracts were washed with water and brine, dried ($MgSO_4$) and concentrated in vacuo. The residue was purified by crystallization from methylcyclohexane/ethyl acetate (which removed the unreacted dimethyl fumarate), bulb to bulb distillation of the mother liquor (at 0.001 mm Hg and 150-160 °C) and column chromatography on silica gel using hexane as an eluent to give the desired diester diastereomer intermediates O as an oil.





A mixture of the diester diastereomers O (41.05 g, 0.12 mol), ethyl acetate (400 mL) and 10% Pd/C (4.2 g) was placed on a Parr shaker and pressurized with H_2 for 2 h. The catalyst was removed by filtration and the

filtrate was concentrated in vacuo to give the saturated diester diastereomer intermediates **P** as an oil.

Anal. Calc'd for $C_{17}H_{19}F_3O_4$: C, 59.30; H, 5.56

Found: C, 50.06; H, 5.60



A solution of the diester diastereomer derivatives **P** (40.1 g, 0.116 mol) in ether (300 mL) was added dropwise to a cooled suspension of LAH (22.15 g, 0.58 mol) and ether (300 mL) under Ar. This mixture was stirred overnight at room temperature. Water (22 mL), followed by 3N NaOH (66 mL) further followed by water (22 mL) were added dropwise and the reaction mixture was stirred for 20 min. The resulting solid precipitate was filtered and the filtrate was washed with successive portions of ether and methylene chloride. The combined organic extracts were concentrated in vacuo, dissolved in methylene chloride, dried ($MgSO_4$) and concentrated in vacuo. The residue was recrystallized from methylcyclohexane/ethyl acetate to give compound **R** as a solid. The mother liquor was purified by column chromatography (Water's Prep 500: methylene chloride/MeOH (20/1)) to give the separated diastereomers **Q**, as an oil, and **R**.

Compound **Q**:

^1H NMR ($CDCl_3$, 300 MHz): δ 7.5-7.3 (m, 4H), 3.8-3.45 (m, 4H), 3.4-3.0 (m, 2H), 2.6-2.45 (m, 1H), 1.95-1.7 (m, 3H), 1.65-1.35 (m, 2H), 1.3-1.15 (m, 1H).

Anal. Calc'd for $C_{15}H_{19}F_3O_2$:

C, 62.49; H, 6.64

Found:


C, 62.25; H, 6.70;

Compound R: 2159071

^1H NMR (CDCl_3 , 300 MHz): δ 7.45-7.3 (m, 4H), 3.65 (d, 2H), 3.45 (t, 1H), 3.05 (m, 1H), 2.95-1.7 (dd, 1H), 2.1 (m, 1H), 1.9 (m, 1H), 1.85-1.65 (m, 3H), 1.62-1.4 (m, 3H).

5

EXAMPLE 6



Cp-11

3a α , 4 β , 7a β -Octahydro-2-methyl-4-(3-trifluoromethylphenyl)-1H-isoindole Monofumarate

- 10 A solution of methanesulfonyl chloride (3.24 mL, 0.04 mol) in methylene chloride (10 mL) was added dropwise to a solution of the diol intermediate R (3 g, 0.01 mol) and triethylamine (7.2 mL, 0.05 mol) in methylene chloride at 0 °C and the reaction mixture was stirred for 1.5 h at 0 °C. The reaction mixture was poured into NaHCO_3 aq. and the resulting organic
- 15 layer was extracted with brine, dried (Na_2SO_4) and concentrated in vacuo. The residue and KI (3.84 g, 0.022 mol) were dissolved in DMF (45 mL), heated to 55 °C for 2 h, cooled to room temperature and transferred to a pressure bottle. Monomethyl amine (g) was bubbled into the vessel and the resulting mixture was heated at 60 °C for 16 h. This mixture was poured
- 20 into water and extracted with ether. The combined organic extracts were washed with water and brine, dried (K_2CO_3) and concentrated in vacuo. The residue was concentrated in vacuo, treated with fumaric acid and crystallized from isopropanol to give the title compound as a solid: mp 178-180 °C.


25 Anal. Calc'd for $\text{C}_{16}\text{H}_{20}\text{NF}_3 \cdot \text{C}_4\text{H}_4\text{O}_4$: C, 60.14; H, 6.06; N, 3.51
 Found: C, 60.35; H, 6.18; N, 3.41

The following general procedure was used to synthesize the compounds listed in Table 2.

PROCEDURE G

5 A solution of methanesulfonyl chloride (0.04 mol) in methylene chloride (10 mL) was added dropwise to a solution of the appropriately substituted diol diastereomer **AD5** or **AD6** (0.01 mol) and triethylamine (0.05 mol) in methylene chloride at 0 °C and the reaction mixture was stirred for 1-3 h at 0°C. The reaction mixture was poured into aqueous NaHCO₃ and the resulting organic layer was extracted with brine, dried (Na₂SO₄ or MgSO₄) and concentrated in vacuo. The residue and KI (0.022 mol) were dissolved in DMF (45-65 mL), heated to 55 °C for 2 h, cooled to room temperature and transferred to a reaction vessel. An appropriately substituted primary amine (0.010-0.10 mol) was added and the resulting mixture was heated at 50-70 °C for 2-16 h. This mixture was poured into water and extracted with a suitable organic solvent such as ether. The combined organic extracts were washed with water and brine, dried (Na₂SO₄ or MgSO₄) and concentrated in vacuo. The residue was concentrated in vacuo, treated with any suitable mineral or organic acid and recrystallized from any appropriate solvent to give the desired compounds.


TABLE 2



Cp-n	(R ^a) _n	R ^c	mp °C	C	H	N	Empirical Formula	MS (MH ⁺)
Cp-7	3-CF ₃	CH ₃	152-54	60.09	6.04	3.43	C ₁₆ H ₂₀ F ₃ N•C ₄ H ₄ O ₄	284
25 Cp-6	3-OMe	Bzl	180-81	70.96	7.17	3.19	C ₂₂ H ₂₇ NO•C ₄ H ₄ O ₄	321


The compound of Table 3 is made by procedure G

TABLE 3



	Cp-n	(R ^a) _n	R ^c	mp °C	C	H	N	Empirical Formula	MS (MH [±])
5	Cp-29	3-OMe	Bzl	180 est.	-	-	-	C ₂₂ H ₂₇ NO·C ₄ H ₄ O ₄	-

EXAMPLE 7

Cp-4

3α, 4α, 7aβ-Octahydro-4-(3-methoxyphenyl)
-1H-indole Monooxalate


- 15 ACE-Cl (0.85 mL, 0.018 mmol) was added dropwise to a cooled solution of 3α, 4α, 7aβ -octahydro-4-(3-methoxyphenyl)-2-phenylmethyl-1H-indole (1.9 g, 0.006 mol) in 1,2-dichloroethane (25 mL). The resulting reaction mixture was heated at reflux for 2 h and left at RT for 16 h. ACE-Cl (0.8 mL) and triethylamine (0.8 mL, 0.006 mmol) were added and the
- 20 resulting reaction mixture was heated at reflux for another 2 h and concentrated in vacuo. The residue was dissolved in MeOH, heated to reflux for 3 h and concentrated in vacuo. This substance was purified by column chromatography using silica gel and methylene chloride/MeOH/NH₄OH (80/20/1) as an eluent. The resulting product was
- 25 dissolved in 2-PrOH and ethereal HCl added. The solid which resulted (Et₃N-HCl) was filtered off. The filtrate was concentrated and converted to the free base by partitioning between Et₂O and 3N NaOH. The free base

was treated with oxalic acid in EtOH. The desired salt crystallized from this mixture as an off white solid: mp 143-145 °C.

Anal. Calc'd for $C_{15}H_{21}NO \cdot C_2H_2O_4$: C, 63.54; H, 7.21; N, 4.36
 Found: C, 63.21; H, 7.12; N, 4.30


5

PROCEDURE H



A solution of cinnamoyl chloride (47 g, 0.28 mol) in methylene chloride (100 mL) was rapidly added to a stirred mixture of methylaminoethanol (24.7 mL, 30 mol), methylene chloride (320 mL), 3N NaOH (180 mL, 0.54 mol) and ice/water 70 mL). The resulting mixture was stirred for 1 h and the aqueous layer was removed. The organic layer was washed with successive portions of dilute HCl and brine, dried ($MgSO_4$) and concentrated in vacuo. The residue was recrystallized from *t*-butyl methyl ether to give compound **S** as a solid.

Anal. Calc'd for $C_{12}H_{15}NO_2$: C, 70.22; H, 7.37; N, 6.82
 Found: C, 70.21; H, 7.42; N, 6.88




A solution of DMSO (18 mL, 0.26 mol) in methylene chloride (80 mL) was added to a stirred solution of oxalyl chloride (12.6 mL, 0.13 mol) in methylene chloride (150 mL) at -50 to -60 °C under Ar over 5 min. The reaction temperature was maintained at a -50 to -60 °C during the addition of a solution of compound **S** (27.02 g, 0.13 mol) in methylene chloride (150 mL) and 25 min of stirring followed by an addition of triethylamine (91 mL, 0.66 mol). The reaction mixture was allowed to warm to room temperature and water (150 mL) was added. The resulting organic layer was separated,



2159071

washed with successive portions of dilute HCl, aqueous NaHCO₃, and brine; dried (MgSO₄), and concentrated in vacuo to give compound T as an oil.

¹H NMR (CDCl₃, 300 MHz): δ 9.7 (s, 1H), 7.8-7.2 (d, 1H), 7.6-7.45 (m, 2H),
5 7.45-7.3 (m, 3H), 6.97-6.92 (d, 1H), 4.3 (s, 2H), 3.25 (s, 3H).



Allyltriphenylphosphonium bromide (88.1 g, 0.23 mol) was added portionwise to a cooled solution of sodium bis(trimethylsilyl)amide
10 (1 M/THF: 230 mL, 0.23 mol) and THF (290 mL) under Ar over 45 m. The mixture was stirred for 30 min and a solution of compound T (42.8 g, 0.21 mol) in THF (120 mL) was added dropwise over 1h. The resulting mixture was poured into ice and extracted with several portions of ether. The combined organic extracts were washed with successive portions of water
15 and brine, dried (MgSO₄) and concentrated in vacuo. The residue was purified by crystallization from *t*-butyl methyl ether and column chromatography on silica gel using hexane/acetone (3/1) as an eluent to give compound U.




A solution of the amide U (6.85 g, 30.12 mmol) in toluene (250 mL) was heated at reflux for 16 h and concentrated in vacuo. The resulting mixture was purified by column chromatography (Waters Prep 500 : acetone/hexane (1/3) eluent) followed by recrystallization of the isolated
25 components from hexane to give diastereomers V and W.

Compound V:


^1H NMR (CDCl_3 , 300 MHz): δ 7.3-7.2 (m, 5H), 7.45-7.3 (m, 3H), 5.9 (m, 1H), 5.85 (m, 1H), 3.5 (m, 1H), 3.1 (m, 2H), 2.9-2.7 (m, 1H), 2.8 (s, 3H), 2.65-2.45 (m, 2H), 2.3-2.15 (m, 1H).

5 Compound W:

^1H NMR (CDCl_3 , 300 MHz): δ 7.4-7.15 (m, 5H), 5.95 (m, 1H), 5.65 (m, 1H), 3.55 (m, 2H), 3.05 (d, 1H), 2.9 (s, 3H), 2.75 (bs, 1H), 2.5-2.4 (m, 1H), 2.3-2.15 (m, 2H).



X



Y

Compounds X and Y were prepared substantially as described in Procedure B, using V or W in place of compound F to give the corresponding saturated product.


Compound X:

15 ^1H NMR (CDCl_3 , 300 MHz): δ 7.35-7.25 (m, 3H), 7.22-7.1 (m, 2H), 3.45-3.35 (m, 1H), 3.32-3.20 (m, 1H), 3.10-3.0 (m, 1H), 2.9 (s, 3H), 2.7 (m, 2H), 1.85-1.6 (m, 3H), 1.45-1.3 (m, 3H).

Compound Y:

20 ^1H NMR (CDCl_3 , 300 MHz): δ 7.35-7.1 (m, 5H), 3.3-3.2 (m, 1H), 3.1-3.02 (t, 1H), 2.9-2.85 (d, 1H), 2.75 (s, 3H), 2.7-2.55 (m, 1H), 2.05-1.9 (m, 3H), 1.5-1.1 (m, 4H).

EXAMPLE 8


Cp-13

3α, 4α, 7αβ-Octahydro-2-methyl-4-phenyl
-1H-isoindole Monofumarate

The title compound was prepared substantially as described in Example 1 using compound X in place of compound E: mp 144-146 °C.

Anal. Calc'd for C₁₅H₂₁N•C₄H₄O₄: C, 68.86; H, 7.60; N, 4.23
Found: C, 68.59; H, 7.56; N, 4.22

EXAMPLE 9


Cp-12

3α, 4α, 7αα-Octahydro-2-methyl-4-phenyl
-1H-isoindole Monofumarate


The title compound was prepared substantially as described in Example 1 using compound Y in place of compound E: mp 166-167 °C.

Anal. Calc'd for C₁₅H₂₁N•C₄H₄O₄: C, 68.86; H, 7.60; N, 4.23
Found: C, 68.62; H, 7.59; N, 4.19

PROCEDURE I





Hexadienal (2.6 g, 27 mmol) was added to a stirred solution of methyl
5 amine (4.23 g, 0.136 mol) and methylamine hydrochloride (9.18 g, 0.136
mol) in methanol (75 mL). The reaction was stirred for 15 min followed by
an addition of sodium cyanoborohydride (2.06 g, 32.6 mmol) and another
hour of stirring. The pH of the reaction mixture was adjusted to pH 7 by the
10 addition of acetic acid and this mixture was stirred for another 4 h. The
resulting mixture was acidified with HCl, stirred for 30 min, basified with
NaOH and extracted with methylene chloride. The combined organic
extracts were dried (K_2CO_3) and concentrated in vacuo to give compound
Z as an oil.



4-Fluorocinnamoyl chloride (3.7 g, 15.0 mmol) was added to a mixture of
compound Z (1.7 g, 15.0 mmol), methylene chloride (50 mL) and 3N NaOH
(20 mL) and the reaction mixture was stirred for 1 h. The organic layer was
15 separated, washed with HCl, filtered, washed with brine, dried ($MgSO_4$)
20 and concentrated in vacuo. The residue was purified by column
chromatography on silica gel using acetone/hexane (15/85) as an eluent
to give compound ZZ as an oil



^1H NMR ($CDCl_3$, 300 MHz): δ 7.7 (dd, 1H), 7.5 (dd, 2H), 7.05 (dd, 2H),
6.85-6.7 (dd, 2H), 6.1 (m, 2H), 5.7 (m, 1H), 5.5 (m, 1H), 4.1 (dd, 2H), 3.0
25 (doubled s, 3H), 1.73 (d, 3H).



Compounds **YY** and **XX** were prepared substantially as described in Procedure H using compound **ZZ** as the amide derivative instead of compound **U**.

Compound **XX**:

^1H NMR (CDCl_3 , 300 MHz): δ 7.15 (m, 2H), 7.0 (m, 2H), 5.85 (m, 1H), 5.7 (m, 1H), 3.3 (m, 2H), 3.17 (t, 1H), 2.85 (s, 3H), 2.75 (m, 1H), 2.5 (m, 2H), 0.61 (d, 3H).



Compounds **VV** and **WW** were prepared substantially as described in Procedure H substituting **XX** or **YY** for compound **V** or **W**.


Compound **VV**:

^1H NMR (CDCl_3 , 300 MHz): δ 7.1 (m, 2H), 6.95 (m, 2H), 3.35 (t, 1H), 2.85 (s, 3H), 2.65 (m, 1H), 2.5 (m, 1H), 2.1 (t, 1H), 1.8 (m, 3H), 1.6 (m, 3H), 0.61 (d, 3H).

Compound **WW**:

Anal. Calc'd for $\text{C}_{16}\text{H}_{16}\text{NFO}$:	C, 73.53; H, 7.71; N, 5.36
Found:	C, 73.55; H, 7.66; N, 5.36

EXAMPLE 10

Cp-19


5 2,5 α -Dimethyl-4 α -(4-fluorophenyl)-3 $\alpha\alpha$. 7 $\alpha\beta$ -
octahydro-1H-isoin-1H-dole Monofumarate

The title compound was prepared substantially as described in Example 2 using compound **WW** in place of compound **F**: mp 193-195 °C.

Anal. Calc'd for C₁₆H₂₂FN•C₄H₄O₄: C, 66.10; H, 7.21; N, 3.85

Found: C, 65.75; H, 7.12; N, 3.95

EXAMPLE 11

Cp-21


10 2,5 β -Dimethyl-4 α -(4-fluorophenyl)-3 $\alpha\alpha$. 7 $\alpha\alpha$ -
octahydro-1H-isoin-1H-dole Monofumarate

- 15 A solution of compound **VV** (0.78 g, 3.0 mmol) in THF (10 mL) was added dropwise to a suspension of LAH (0.34 g, 9.0 mmol) and THF (5 mL) under Ar. The reaction mixture was heated to reflux for 4 h and cooled to room temperature. Water (0.34 mL), followed by 3N NaOH (1.0 mL) further followed by water (0.34 mL) were added dropwise to the stirred reaction
- 20 mixture. The resulting solid precipitate was filtered and the mother liquor

was concentrated in vacuo. The residue was treated with fumaric acid in isopropanol to give the title compound as a solid: mp 199-203 °C.

Anal. Calc'd for $C_{16}H_{22}FN \cdot C_4H_4O_4$: C, 66.10; H, 7.21; N, 3.85
Found: C, 66.29; H, 7.19; N, 3.72

5


EXAMPLE 12

2.5 α -Dimethyl-4 α -(4-fluorophenyl)-2.3.3 α -4.5.7 α β -
hexahydro-1H-isoindole Monofumarate


- 10 A solution of compound XX (2.8 g, 10.8 mmol) in THF (25 mL) was added dropwise to a suspension of LAH (1.23 g, 32 mol) and THF (25 mL) under Ar. The reaction was stirred at reflux for 4 h and cooled to room temperature. Water (1.23 mL), followed by 3N NaOH (3.75 mL) further followed by water (1.23 mL) were added dropwise to the stirred reaction
- 15 mixture. The resulting solid precipitate was filtered and the mother liquor was concentrated in vacuo. The residue was treated with fumaric acid in isopropanol to give the title compound as a solid: mp 187-188 °C.

Anal. Calc'd for $C_{16}H_{20}FN \cdot C_4H_4O_4$: C, 66.47; H, 6.69; N, 3.88
Found: C, 66.56; H, 6.71; N, 3.75

PROCEDURE J




5 *trans, trans*-1,4- Diphenyl-1,3-butadiene (10.3 g, 50.0 mmol), N-methylmaleimide (6.6 g, 60 mmol) and xylenes (150 mL) were heated at 130 °C under N₂ for 15 h. The mixture was cooled and the resulting precipitate, compound UU was isolated and used without further purification.



10

10 % Pd/C (1 g) was added to a solution of compound UU (9.94 g, 31.0 mmol) in ethyl acetate (125 mL) and the mixture was pressurized with H₂ (19.75 psi) for 40 min and left at room temperature for 16 h. An additional portion of 10 %Pd/C (1 g) was added and the resulting mixture was
15 pressurized (60 psi) for 16 h. The catalyst was filtered away and the filtrate was concentrated in vacuo to give compound TT as a solid, which was used without further purification.

EXAMPLE 13



4β, 7β-Diphenyl-2-methyl-3α, 7α-octahydro-
1H-isoindole 0.8 fumarate

5

10


15

A solution of compound TT (8 g, 25 mmol) in anhydrous THF (100 mL) was added dropwise to a suspension of LAH (4.98 g, 131 mmol) and THF (80 mL). This stirred mixture was heated at reflux for 4 h under N₂ and cooled to room temperature. Water (5.0 mL), followed by 3N NaOH (5.0 mL) further followed by water (15 mL) were added dropwise and the reaction mixture was stirred for 1.5 h. The resulting solid precipitate was filtered and the filtrate was washed with successive portions of THF, dried (K₂CO₃) and concentrated in vacuo. The residue was purified by column chromatography using silica gel and 5 % MeOH/methylene chloride as an eluent to give the free base of the title compound as a solid. This solid was dissolved in isopropanol, treated with fumaric acid and MeOH to give the title compound as a solid: mp 208-13 °C.

Anal. Calc'd for C₂₁H₂₅N•0.8 C₄H₄O₄: C, 75.52; H, 7.76; N, 3.64
 Found: C, 75.64; H, 7.40; N, 3.64


20

PROCEDURE K




Allyltriphenylphosphonium bromide (452 g, 1.3 mol) was added portionwise under Ar to a cooled solution of sodium bis(trimethylsilyl)amide (1.0 mol/THF 1.18 L, 1.18 mol) and THF (1.5 L). The resulting mixture was stirred for another 35 min at 0 °C and a solution of 3-methylbenzaldehyde (129 g, 1.75 mol) in THF (100 mL) was added (dropwise) to the mixture. The reaction mixture was stirred for 2.5 h at 0 °C and poured into ice/water. The organic layer was removed and washed with successive portions of water and brine, dried (MgSO₄) and concentrated in vacuo. The residue was dissolved at reflux in *t*-butylmethylether and cooled to 0°C. The resulting precipitate (triphenyl phosphine oxide) was removed by filtration and the filtrate was concentrated in vacuo. The residue was purified by column chromatography on silica gel using hexane/acetone (10/1) as an eluent to give the diene **RR**, as an oil.

Anal. Calc'd for C₁₁H₁₀: C, 91.61; H, 8.39
Found: C, 91.46; H, 8.40





A mixture of 1-(3-methylphenyl)-1,3-butadiene (137 g, 0.96 mol), dimethyl fumarate (151.7 g, 1.06 mol) and ethylene glycol (685 mL) was heated at 60 °C for 16 h. The reaction mixture was poured into water and the organic extract was washed with water and brine, dried (MgSO₄) and concentrated in vacuo. The residue was purified by crystallization from methylcyclohexane/ethyl acetate (which removed the unreacted dimethyl fumarate), bulb to bulb distillation of the mother liquor (at 0.001 mm Hg and 90-140 °C) and column chromatography on silica gel using hexane as an eluent to give the desired diester diastereomeric intermediates **QQ** as an oil.



A mixture of the diester diastereomers **QQ** (78.0 g, 0.27 mol), ethyl acetate (600 mL) and 10% Pd/C (7.8 g) was placed on a Parr shaker and
5 pressurized with H₂ (60 psi) for 2 h. The catalyst was removed by filtration, the filtrate was concentrated in vacuo and the residue was purified by column chromatography (silica gel, hexane:acetone 1:1) to give the saturated diester diastereomeric intermediates **PP** as an oil.

Anal. Calc'd for C₁₇H₂₂O₄: C, 70.32; H, 7.64

Found: C, 70.55; H, 7.58



A solution of the diester diastereomeric derivatives **PP** (70.12 g, 0.24 mol) in ether (600 mL) was added dropwise to a cooled suspension of LAH (45.2 g, 1.19 mol) and ether (600 mL) under Ar over 2.5 h. This mixture was
15 stirred overnight at room temperature. Water (45 mL), followed by 3N NaOH (135.0 mL) further followed by water (45 mL) were added dropwise and the reaction mixture was stirred for 1 h. The resulting solid precipitate was filtered off and the filtrate was washed with successive
20 portions of THF. The combined organic extracts were washed with water, dried (MgSO₄) and concentrated in vacuo. The residue was purified by chromatography on a Waters Prep 500 HPLC using a CH₂Cl₂/MeOH gradient followed by recrystallization from methylcyclohexane/ethyl acetate to give the separated diastereomers **OO** and **NN** as solids.

Compound OO:

^1H NMR (CDCl_3 , 300 MHz): δ 7.2-7.1 (m, 1H), 7.05-6.9 (m, 3H), 3.8-3.45 (m, 4H), 3.25 (m, 1H), 2.3 (s, 3H), 1.9-1.1 (m, 5H)

Compound NN:

5 ^1H NMR (CDCl_3 , 300 MHz): δ 7.3-6.95 (m, 4H), 3.8 (m, 2H), 3.55 (m, 2H), 2.95 (m, 1H), 2.35 (s, 3H), 2.15 (m, 1H), 2.0 (m, 2H), 1.85-1.35 (m, 3H)


Anal. Calc'd for $\text{C}_{15}\text{H}_{22}\text{O}_2$:

C, 76.88; H, 9.46

Found:

C, 77.21; H, 9.53

EXAMPLE 14



Cp-24


3 α , 7 α Octahydro-2-methyl-4 α -(3-methylphenyl)-1H-indole Monofumarate

15 A solution of methanesulfonyl chloride (2.5 mL, 32.3 mmol) in methylene chloride (7 mL) was added to a solution of compound OO (3.45 g, 14.7 mmol) and triethylamine (4.5 mL, 32.3 mmol) in methylene chloride (40 mL) at 0 °C under Ar. The mixture was stirred at 0 °C for 2 h and poured into NaHCO_3 /ice. The organic layer was separated, washed with successive portions of water and brine, dried (Na_2SO_4) and concentrated

20 in vacuo. The residue was dissolved in EtOH (40 mL), placed in a Parr bottle and gaseous methylamine was bubbled into the solution for 2 min. This mixture was sealed and heated at 80 °C for 16 h and concentrated in vacuo. The resulting residue was partitioned between ether and 3N NaOH. The organic layer was washed with water and brine, dried (K_2CO_3) and concentrated

25 in vacuo. The residue was treated with fumaric acid and recrystallized from isopropanol and ether to give the title compound as a solid: mp 145-148 °C.

Anal. Calc'd for $C_{16}H_{23}N \cdot C_4H_4O_4$: C, 69.54; H, 7.88; N, 4.05
Found: C, 69.84; H, 7.89; N, 4.03

EXAMPLE 15Cp-23

3α, 7α, 8α Octahydro-2-methyl-4β-(3-methylphenyl)-
1H-isoindole Monofumarate

A solution of methanesulfonyl chloride (2.9 mL, 37.4 mmol) in methylene chloride (8 mL) was added to a solution of compound NN (4.0 g, 17 mmol) and triethylamine (5.2 mL, 37.4 mmol) in methylene chloride (40 mL) at 0 °C under Ar. The mixture was stirred at 0 °C for 2.5 h and poured into NaHCO₃/ice. The organic layer was separated, washed with successive portions of water and brine, dried (Na₂SO₄) and concentrated in vacuo. The residue was dissolved in EtOH (40 mL), placed in a Parr bottle and gaseous methylamine was bubbled into the solution. This mixture was sealed and heated at 80 °C for 16 h and concentrated in vacuo. The resulting residue was partitioned between ether and 3N NaOH. The organic layer was washed with water and brine, dried (K₂CO₃) and concentrated in vacuo. The residue purified by a combination of techniques which include column chromatography, treatment with fumaric acid and recrystallization from isopropanol to give the title compound as a solid: mp 158-160 °C.

Anal. Calc'd for $C_{16}H_{23}N \cdot C_4H_4O_4$: C, 69.54; H, 7.88; N, 4.05
Found: C, 69.53; H, 7.89; N, 3.98

PROCEDURE L

The following general procedure was used to synthesize the compounds listed in Tables 4 and 5.

A mixture of an appropriately substituted butadiene derivative **AD1** (1.0 mol: obtained commercially, prepared from a literature procedure or prepared substantially as described in procedure K), dimethyl fumarate (1.1 mol) and ethylene glycol (720 mL) was heated at 60 °C for 10-24 h. The reaction mixture was poured into water and the organic extract was washed with water and brine, dried with a suitable drying agent and concentrated in vacuo. The residue was purified by a combination of crystallization from a suitable solvent, vacuum distillation and column chromatography to give the desired diester diastereomeric intermediates **AD3** and **AD4**.

A mixture of the diester diastereomers **AD3** and **AD4** (1.0 mol), ethyl acetate (2.2 L) and 10% Pd/C (28.86 g) was placed on a Parr shaker and pressurized with H₂ (60 psi) for 2-24 h. The catalyst was removed by filtration, the filtrate was concentrated in vacuo and the residue was purified by column chromatography to give the saturated diester diastereomeric intermediates.

A solution of the saturated diester diastereomeric derivatives (1.0 mol) in a suitable solvent such as ether (2.4 L) was added dropwise to a cooled suspension of LAH (4.8 mol) and ether (2.4 L) under Ar over 2.5-4.5 h. This mixture was stirred overnight at room temperature. Water (180 mL), followed by 3N NaOH (540 mL) further followed by water (180 mL) were added dropwise and the reaction mixture was stirred for 1-3 h. The resulting solid precipitate was filtered and the filtrate was washed with successive portions of THF. The combined organic extracts were washed with water, dried with a suitable drying agent and concentrated in vacuo. The residue was purified by a combination of column chromatography and recrystallization to give the separated diastereomers **AD5** and **AD6**.


A solution of methanesulfonyl chloride (22.0 mmol) in methylene chloride (4.76 mL) was added to a solution of the appropriately substituted separated diastereomer (10.0 mmol) and triethylamine (22.0 mmol) in methylene chloride (27.2 mL) at 0 °C under Ar. The mixture was stirred at 0 °C for 2 h and poured into NaHCO₃/ice. The organic layer was separated, washed with successive portions of water and brine, dried (Na₂SO₄) and concentrated in vacuo. The residue was dissolved in EtOH (40 mL), placed in a Parr bottle and gaseous methylamine was bubbled into the solution for 2 min. This mixture was sealed and heated at 80 °C for 16 h and concentrated in vacuo. The resulting residue was partitioned between a suitable organic solvent and 3 N NaOH. The organic layer was

2159071

washed with water and brine, dried with a suitable drying agent and concentrated in vacuo. The residue was treated with fumaric acid and recrystallized from an appropriate solvent to give the desired 4-arylisoindole.


5

TABLE 4




Cp-n	(R ^a) _n	R ^c	mp °C	C	H	N	Empirical Formula	MS (MH [±])
Cp-16	4-CF ₃	CH ₃	150-52	57.95	5.83	3.69	C ₁₆ H ₂₀ F ₃ N•C ₂ H ₂ O ₄	284
Cp-18	3-CF ₃	n-Bu	139-44	59.58	6.88	3.39	C ₁₉ H ₂₆ F ₃ N•C ₂ H ₂ O ₄	326
10 Cp-15	3,4-di Cl	CH ₃	184-85	57.01	5.79	3.50	C ₁₅ H ₁₉ Cl ₂ N•C ₄ H ₄ O ₄	
Cp-25	3-CF ₃	iso-Bu	139-41	61.82	6.65	3.23	C ₁₈ H ₂₄ F ₃ N•C ₄ H ₄ O ₄	312

TABLE 5




Cp-n	(R ^a) _n	R ^c	mp °C	C	H	N	Empirical Formula	MS (MH [±])
15 Cp-17	4-CF ₃	CH ₃	150-52	57.90	5.94	3.75	C ₁₆ H ₂₀ F ₃ N•C ₂ H ₂ O ₄	284
Cp-14	3,4-di Cl	CH ₃	184-85	57.08	5.77	3.47	C ₁₅ H ₁₉ Cl ₂ N•C ₄ H ₄ O ₄	-
Cp-22	4-CF ₃	(CH ₂) ₂ CH(Ph) ₂	164-66	70.77	6.26	2.57	C ₃₀ H ₃₂ F ₃ N•C ₄ H ₄ O ₄	284
Cp-30	3-CH ₃	(CH ₂) ₂ N(CH ₃) ₂	253-55	63.89	9.50	9.50	C ₂₀ H ₃₂ N ₂ •2HCl•0.02H ₂ O	301

PROCEDURE M




MM

A solution of allyltriphenylphosphonium bromide (421.5 g, 1.1 mol) in dry THF (500 mL) was added portionwise under Ar to a cooled (5-10 °C) solution of sodium bis(trimethylsilyl)amide (1.0 mol/THF: 1000 mL, 1.0 mol) and THF (1.2 L). The resulting mixture was stirred for another 1 h at 10 °C and a solution of 4-methylthiobenzaldehyde (152 g, 1.0 mol) in THF (500 mL) was added to the mixture over 1.5 h. The reaction mixture was stirred for 1.75 h at 10 °C and partitioned between water and ether. The organic layer was removed and the resulting aqueous layer was washed with several portions of ether. The combined organic layers were dried (MgSO₄) and concentrated in vacuo. The residue which partially crystallized upon standing was washed with several portions of hexane and filtered. The filtrate was concentrated in vacuo and purified by a combination of column chromatography on silica gel using hexane as an eluent and recrystallization from MeOH/acetonitrile to give diene MM, as a solid.




LL

A mixture of compound MM (17.5 g, 0.1 mol), dimethyl fumarate (14.9 g, 0.1 mol) and ethylene glycol (150 mL) was heated at 60 °C for 33 h. The reaction mixture was poured into water and extracted with ether. The combined organic extracts were dried (MgSO₄) and concentrated in vacuo. The residue was purified by column chromatography on silica gel using hexane/ethyl acetate as an eluent to give the desired diester intermediate LL as a mixture of diastereomers.



JJ




KK

A solution of the diester diastereomeric derivatives LL (34.0 g, 0.106 mol) in ether (340 mL) was added dropwise to a cooled suspension of LAH (21.2 g, 0.56 mol) and ether (210 mL) under Ar. This mixture was stirred overnight at room temperature. Water (21 mL), followed by 3N NaOH (21 mL) further followed by water (63 mL) were added dropwise to the stirred reaction mixture. The resulting solid precipitate was filtered and the filtrate was washed with successive portions of ether and methylene chloride. The combined organic extracts were concentrated in vacuo, dissolved in methylene chloride, dried (MgSO₄) and concentrated in vacuo. The residue was purified by column chromatography (Waters Prep 500: methylene chloride/acetone, 90:10), to give the separated diastereomers JJ and KK as oils.

15

EXAMPLE 16

Cp-27

3α, 4α, 7α Octahydro-2-methyl-4-(4-methylthiophenyl)-1H-isoindole Monofumarate


The title compound was prepared substantially as described in Example 14, where compound JJ is used in place of compound OO to give the title compound as a solid: mp 183-185 °C.

¹H NMR (DMSO-d₆:300 MHz) 7.25 (d, 2H), 7.12 (d, 2H), 6.45 (s, 2H), 5.85 (m, 1H), 5.55 (d, 1H), 3.40 (m, 2H), 3.00 (m, 2H), 2.85 (t, 1H), 2.65 (s, 3H), 2.45 (s, 3H), 2.42 (m, 1H), 2.15 (m, 1H), 2.00 (m, 2H).

Anal. Calc'd for C₁₆H₂₁NS•C₄H₄O₄: C, 63.98; H, 6.71; N, 3.73



Found: C, 63.89; H, 6.80; N, 3.57

PROCEDURE N



Compound II was prepared essentially as described in Procedure H using cinnamyltriphenylphosphonium chloride in place of allyltriphenylphosphonium bromide to give compound II as an oil.


¹H NMR (CDCl₃, 300 MHz): δ 7.8-7.1 (m, 12H), 6.95-6.3 (m, 4H), 4.4, 4.3, 4.2, 4.15, (dd of d, 2H), 3.11 (s, 3H), 3.08 (s, 3H), 3.06 (s, 3H).



Compounds HH and GG were prepared substantially as described in procedure H using compound II in place of compound U.

Compound GG:

¹H NMR (CDCl₃, 300 MHz): δ 7.1 (m, 6H), 6.65 (m, 4H), 6.15 (m, 1H), 5.32 (m, 1H), 3.8 (m, 1H), 3.6 (m, 1H), 3.45 (m, 1H), 3.25 (m, 1H), 2.9 (m, 1H), 2.8 (s, 3H), 2.7 (t, 1H).


**FF**

Compound **FF** was prepared substantially as described in procedure B using compound **GG** in place of compound **F**.

5 Compound **FF**:

¹H NMR (CDCl₃, 300 MHz): δ 7.0 (m, 6H), 6.85 (m, 2H), 6.7 (m, 2H), 3.35 (m, 1H), 3.25 (m, 3H), 2.8 (s, 3H), 2.7 (t, 1H), 2.2 (m, 2H), 2.1 (m, 3H).

EXAMPLE 17



**Cp-26**

4α,5α-Diphenyl-2-methyl-3α,7αβ-octahydro-1H-isindole Monofumarate

The title compound was prepared substantially as described in Example 11 using compound **FF** in place of compound **VV**: mp 78-79 °C.

15 Anal. Calc'd for C₂₁H₂₅N: C, 86.55; H, 8.64; N, 4.81
 Found: C, 86.57; H, 8.45; N, 4.73

PROCEDURE O




- A solution of methanesulfonyl chloride (14.1 mL, 0.18 mol) in methylene chloride (35 mL) was added to a solution of compound **OO** (19.46 g, 0.083 mol) and triethylamine (24.2 mL, 0.18 mol) in methylene chloride (175 mL) at 0 °C under Ar. The mixture was stirred at 0 °C for 2 h and poured into NaHCO₃/ice. The organic layer was separated, washed with successive portions of water and brine, dried (Na₂SO₄) and concentrated in vacuo. The residue was dissolved in EtOH (190 mL) and *R*-(+)- α -methylbenzylamine (74 mL, 0.58 mol) was added. This mixture was heated at 60 °C under Ar for 16 h and concentrated in vacuo. The resulting residue was partitioned between ether and 3N NaOH. The organic layer was washed with water and brine, dried (K₂CO₃) and concentrated in vacuo. The residue was passed through a Water's Prep column (to remove some of the unreacted amine) and dissolved in ether. CO₂ was bubbled into the ethereal solution and the resulting solid was removed by filtration. The filtrate was concentrated in vacuo and purified by column chromatography on a Water's Prep 500 using 10 % acetone/hexane as an eluent. There were obtained two spots corresponding to compounds **EE** and **DD**.

Compound EE

Anal. Calc'd for C₂₃H₂₉N: C, 86.47; H, 9.15; N, 4.38

Found: C, 86.22; H, 9.22; N, 4.39



10

Cp-24± or Cp-24-

15


25

Cp-24-

Anal. Calc'd for C₁₆H₂₃N/C₄H₄O₄: C, 69.54; H, 7.88; N, 5.05.

Found: C, 69.47; H, 8.01; N, 3.89.

PROCEDURE P




5

Compound **DD** or **EE** (7.15 g, 0.022 mol) and ammonium formate (9.9 g, 0.154 mol) were added to a suspension of 10 % Pd/C (7.15 g) and MeOH (250 mL) under Ar and the resulting mixture was heated to reflux for 1 h.

10 The catalyst was removed by filtration and the filtrate was concentrated in vacuo. The residue was partitioned between methylene chloride and aqueous NaOH. The organic layer was washed with successive portions of water and brine, dried (Na₂SO₄) and concentrated in vacuo. 10 %Pd/C (0.3 g) was added to a solution of the residue in MeOH (60 mL) and this

15 mixture was placed on a Parr shaker and pressurized with H₂ (50 psi) at 60 °C for 16 h. The catalyst was removed by filtration and the filtrate was concentrated in vacuo to give compound **BB** as a green solid: mp 166-170 °C.

EXAMPLE 19



20

Cp-24± or Cp-24-

(+)3α, 4α, 7α Octahydro-2-methyl-4-(3-methylphenyl)-
1H-isoindole Monofumarate

2159071

The title compound was prepared essentially as described in example 18 except that compound **CC** was replaced with compound **BB**, respectively. The product was isolated as a solid: mp 144-146 °C, $[\alpha]^{25}_D = (+)54.05$.

¹H NMR (DMSO d₆, 300 MHz): δ 7.2 (t, 1H), 7.1-7.0 (m, 3H), 6.45 (s, 2H), 3.35 (dd, 1H), 2.9-2.7 (m, 3H), 2.65 (s, 3H), 2.5-2.4 (m, 1H), 2.3 (s, 3H), 2.1-1.95 (m, 1H), 1.9-1.75 (m, 4H), 1.45 (t, 2H), 1.2 (m, 1H).


Cp-24+

Anal. Calc'd for C₁₆H₂₃N/C₄H₄O₄: C, 69.54; H, 7.88; N, 5.05.

Found: C, 69.69; H, 8.08; N, 3.99.

10

* EXAMPLE 20



(1) 2-Methyl-4 α -(4-methylsulfanyphenyl)-3 α , 4,7,7 α -tetrahydroisoindole-1,3-dione. A 17.6 g (0.1 mole) sample of a mixture of *cis* and *trans* 1-(4-methylthiophenyl)-1,3-butadiene and 11.1g (0.1 mole) of N-methylmaleimide were added to 100 mL of ethylene glycol and heated at 100 °C for 42 h. The mixture was partitioned between CH₂Cl₂ and water, and organic layer was separated, and dried (MgSO₄). The organic solution was evaporated *in vacuo* and the diastereoisomers separated on the Waters Prep 500 (SiO₂) eluting with 10% acetone: 90% CH₂Cl₂ to give 4 g (28% yield) of a yellow oil.

^1H NMR (CDCl_3): δ 2.5 (m, 5H); 3.0 (s, 3H); 3.1 (m, 1H); 3.25 (dd, 1H); 4.0 (m, 1H); 6.05 (m, 2H); 7.2 (m, 4H).

MS-EI, m 287.

5 (2) 2-Methyl-4 α -(4-methylsulfanyphenyl)-2,3,3 α ,4,7,7 α -hexahydro-1H-isoindole and 2-Methyl-4-(4-methylsulfanyphenyl)-2,3,3 α ,6,7,7 α -hexahydro-1H-isoindole (88%: 12%). A solution of 3.65 g (0.0127 mole) of 2-methyl-4 β -(4-methylsulfanyphenyl)-3 α ,7 α -tetrahydroisoindole-1,3-dione in 50 mL of THF was added portionwise to a suspension of 2.53 g (0.0667 mole) lithium aluminum hydride in 25 mL of THF. The mixture was
10 refluxed for 4.5 h. To the mixture at room temperature was added dropwise 2.53 mL H_2O , 2.53 mL of 3N NaOH, then 7.5 mL of H_2O . The inorganic solid was filtered off, and the filter cake washed with CH_2Cl_2 . The filtrates were combined, dried (K_2CO_3), and evaporated *in vacuo* to a yellow oil. Flash chromatography (SiO_2) eluting with 1-10-90 : NH_4OH - MeOH - CH_2Cl_2
15 gave 1.56g (48% yield) of an oil. A sample of 0.699 g of fumaric acid was added to the oil in methanol and ether added to precipitate the salt. Recrystallization from methanol gave 0.79g (24% yield) of a tan solid, mp 120-124 $^\circ\text{C}$.

20 ^1H NMR ($\text{DMSO } d_6$): δ 1.92-2.02 (d, 1H); 2.2-2.3 (m, 1H); 2.3-2.42 (m, 1H); 2.45 (s, 3H); 2.5-2.58 (m, 1H); 2.68 (s, 3H); 2.9-3.08 (m, 3H); 3.12-3.28 (m, 2H); 5.61-5.68 (d, 1H); 5.82-5.68 (d, 1H); 5.82-5.9 (m, 1H); 6.5 (s, 2.5H); 7.14-7.18 (d, 2H); 7.22-7.26 (d, 2H).

Anal. Cal'd for $\text{C}_{16}\text{H}_{21}\text{NS}/1.2 \text{ C}_4\text{H}_4\text{O}_4$: C, 63.03; H, 6.74; N, 3.55;

Found: C, 62.66; H, 6.52; N, 3.53.

25 (3) 2-Methyl-4-(4-methylsulfanyphenyl)-2, 3, 3 α , 6, 7, 7 α -hexahydro-1H-isoindole, Cp-25. A 110 mg (0.00424 mole) of 2-methyl-4 α -(4-methylsulfanyphenyl)-2,3, 3 α , 4 α ,7, 7 α -hexahydro-1H-isoindole was dissolved in 0.425 mL (0.00425 mole) of a solution of 1 M potassium t-butoxide in THF and refluxed for 6 h, then allowed to stand at room
30 temperature overnight. The solution was partitioned between water-methylene chloride, the methylene chloride layer separated, and dried (K_2CO_3). Evaporation of the CH_2Cl_2 under a stream of nitrogen gave 90 mg (82% yield) of an oil, which was dissolved in 2-propanol and treated with


2159071

40 mg of fumaric acid. The salt was dried and isolated as a solid: mp 164-165 °C.

¹H NMR (DMSO d₆): δ 1.4-1.6 (m, 1H); 1.62-1.72 (m, 1H); 2.1-2.2 (m, 2H); 2.4-2.6 (m, 2H); 2.48 (s, 3H); 2.52 (s, 3H); 2.8-2.9 (m, 1H); 3.15-3.25 (m, 2H); 3.4-3.5 (m, 1H); 6.2-6.25 (m, 1H); 6.55 (s, 2H); 7.15-7.22 (d, 2H); 7.3-7.35 (d, 2H).

Anal. Cal'd for C₁₆H₂₁NS/C₄H₄O₄: C, 63.98; H, 6.71; N, 3.73
Found: C, 63.82; H, 6.61; N, 3.67

PROCEDURE Q




5 4α-(3-Methoxyphenyl)-2-methyl-3α,4,7,7α-tetrahydro-1H-isoin-
1,3(2H)-dione.

10 The *cis*-1-(3-methoxyphenyl)-1,3-butadiene (10.0 g, 0.06 mole), diene G, from procedure D was heated to 100°C in 60 mL ethylene glycol with 7 g (0.06 mole) N-methylmaleimide overnight. After cooling the reaction was partitioned between Et₂O and H₂O. The organics were separated off and washed with H₂O, brine and dried (MgSO₄). The solvent was evaporated in vacuo. The product was passed through two flash chromatography columns on silica gel (8:1 hexane:acetone then 1:1 hexane: acetone).

Mass spectrum (CI-CH₄) m/z 272 (M + 1).

15 ¹H NMR (CDCl₃) δ 7.25 (t, 1 H); 6.9-6.7 (m, 3 H); 6.05 (d, 2 H); 4.0 (m, 1 H); 3.8 (s, 3 H); 3.3 (dd, 1 H); 3.1 (td, 1 H); 3.0 (s, 3 H); 2.5 (m, 2 H).

Example 21




4 α -(3-Methoxyphenyl)-2-methyl-3,3 α ,4,7,7 α -hexahydro-1H-isoindole
fumarate

A solution of 5 g (0.018 mole) 4 α -(3-methoxyphenyl)-2-methyl-3 α ,4,7,7 α -
tetrahydro-1H-isoindole-1,3(2H)-dione, **ZZZ**, in 25 mL THF was added
5 dropwise to a suspension of 7.1 g (0.018 mole) LAH in 70 mL THF. The
reaction was stirred overnight under argon. The reaction was quenched
with added 7.0 mL H₂O, 21 mL 3N NaOH and 7 mL H₂O. After stirring 45
minutes the solid was filtered off and the filter cake washed well with THF.
The filtrate was washed with H₂O, brine, and dried (K₂CO₃). The solvent
10 was removed in vacuo and the residue was flash chromatographed on
silica gel (90 : 10 :1, CH₂Cl₂ : MeOH : NH₄OH). The free base was
converted to the fumarate salt in 2-PrOH/Et₂O to give 3.28 g of product: mp.
91-93°C.

Mass spectrum (CI-CH₄) m/z 244 (M + 1).

15 ¹H NMR (Me₂SO d-6) δ 7.25 (t, 1 H), 6.8 (m, 3 H), 6.5 (s, 2 H), 5.9 (m, 1 H),
5.7(bd, 1 H), 3.7(s, 3 H), 3.25-3.1(m, 2 H), 3.0 (m, 3 H), 2.5 (m, 1 H), 2.65 (s,
3 H), 2.4-2.2 (m, 2 H), 2.0 (m, 1 H). Anal calcd for C₁₆H₂₁NO.C₄H₄O₄: C,
66.84; H, 7.01; N, 3.90. Found: C, 66.84; H, 6.93; N, 3.89.

PROCEDURE R



TTT

2-(Phenylmethyl)-3 α ,7 α -octahydro-1H-isoindol-4-one.

A solution of N-methoxybutyl-N-(trimethylsilyl)benzylamine (90.06 g; 0.32
mole) and 2-cyclohexene-1-one (25 mL; 0.25 mole) in 320 mL of CH₂Cl₂
25 and 16 mL of 1% TFA in CH₂Cl₂ was heated under reflux for 2 h. The
reaction was cooled and approximately 20 g of K₂CO₃ was added and the
reaction stirred for 45 m. The solid was filtered off and the solvent
evaporated in vacuo. The residue was partitioned between Et₂O/3N NaOH,


the organics were separated off and washed with H₂O and brine and dried (K₂CO₃). The solvent was removed in vacuo. The oil was treated with oxalic acid in 2-PrOH and EtOH. The solid was collected to give 35.01 g of a solid: mp. 129-130° C.

5 Mass spectrum (Cl-CH₄) m/z 229 (M + 1).

¹H NMR (CDCl₃) δ 7.3 (m, 5 H); 3.6 (s, 2 H); 2.9-2.6 (m, 4 H); 2.4 (t, 2 H); 2.25 (m, 2 H); 1.9-1.8 (m, 3 H); 1.4 (m, 1 H).

Anal calcd for C₁₅H₁₉NO.C₂H₂O₄: C, 63.94; H, 6.63; N, 4.39.

Found: C, 63.7; H, 6.62; N, 4.24.




YYY

2-Methyl-3α,7α-octahydro-1H-isoindol-4-one

2-Benzyl-3α,7α-octahydro-1H-isoindol-4-one, TTT, (2.5 g, 0.011 mole) and 2.1 g (0.011 mole) methyl tosylate were combined in 30 mL EtOAc and stirred overnight. An additional 1.2 g (0.0064 mole) of methyl tosylate was added and the reaction stirred for 72 h. The solid was filtered off and washed well with Et₂O. The solid was taken up in 30 mL absolute EtOH and placed over 0.4 g 10 % palladium on carbon. This was placed on a Parr shaker and shaken for 1.5 h under 50 psi of hydrogen. The catalyst was filtered off and the filtrate was evaporated in vacuo. The residue was partitioned between Et₂O and 3N NaOH, the organics were separated off and washed with H₂O and brine and dried (K₂CO₃). The solvent was evaporated in vacuo. The residue was distilled in a bulb to bulb distillation apparatus to give 1.31 g of a clear oil.

25 Mass spectrum (Cl-CH₄) m/z 154 (M + 1).

¹NMR (CDCl₃) δ 2.9-2.7 (m, 5H); 2.5-2.4 (m, 3 H); 2.3 (s, 3 H); 2.3 (m, 1 H); 2.0-1.8 (m, 2 H); 1.5-1.4 (m, 1 H).



XXX

4α-(4-Fluorophenyl)-4β-hydroxy-2-methyl-3α,7α-octahydro-1H-isoindole
fumarate

- 5 A solution of 3.3 mL (0.029 mole) of 4-bromofluorobenzene in 15 mL THF was added dropwise to a solution of 18.75 mL (0.029 mole) of 1.6M n-butyllithium at -78°C. After stirring for one hour, this solution was added via cannula to a solution of 1.5 g (0.0095 mole) of 2-methyl-3α,7α-octahydro-1H-isoindol-4-one, YYY, in 30 mL THF also at -78°C. After stirring for 2 h
- 10 the reaction was poured into H₂O, the organics were separated and washed with H₂O, brine and dried (K₂CO₃). The solvent was evaporated in vacuo. The residue was passed through a flash chromatography column on silica gel (80 : 20 : 2 CH₂Cl₂ : MeOH : NH₄OH). The product was converted to the fumarate salt in 2-PrOH: mp. 192-193°C.

- 15 Mass spectrum (CI-CH₄) m/z 251 (M + 1).


¹H NMR (Me₂SO d₆) δ 7.55 (m, 2 H); 7.15 (m, 2 H); 6.5 (s, 2 H); 3.3 (t, 1 H); 3.1-3.0 (m, 2 H); 2.9 (d, 1 H); 2.7 (s, 3 H); 2.6 (m, 1 H); 2.5 (m, 1 H); 1.85-1.6 (m, 5 H); 1.35 (m, 1 H).

Anal calcd for C₁₅H₂₀FNO.C₄H₄O₄: C, 62.45; H, 6.62; N, 3.83.

20

Found: C, 62.14; H, 6.61; N, 3.77.


Example 22

Cp-324β-(4-Fluorophenyl)-2-methyl-3α,7α-octahydro-1H-isoindole fumarate

- 5 4α-(4-Fluorophenyl)-4β-hydroxy-2-methyl-3α,7α-octahydro-1H-isoindole, **XXX**, (0.74 g, 0.0032 mole), was added to a Parr bottle containing 0.37 g 10% palladium on carbon, 50 mL HOAc and 7.5 mL perchloric acid. The mixture was shaken under 50 psi of hydrogen overnight. The catalyst was filtered off and the filtrate concentrated in vacuo. The residue was
- 10 partitioned between Et₂O and 3N NaOH. The organics were washed with H₂O, brine and dried (K₂CO₃). The solvent was evaporated in vacuo. After a flash chromatography on silica gel (90:10:1, CH₂Cl₂:MeOH:NH₄OH) the product was converted to the fumarate salt in 2-PrOH to give 430 mg of a white solid: mp. 157-159°C.
- 15 Mass spectrum (CI-CH₄) m/z 235 (M + 1).

¹H NMR (Me₂SO d-6) δ 7.25 (m, 2 H); 7.1 (m, 2 H); 6.5 (s, 2 H); 3.3-3.1 (m, 2 H); 3.15 (m, 1 H); 2.9 (bd, 1 H); 2.65 (m, 1 H); 2.6 (s, 3 H); 2.3 (m, 2 H); 1.8 (m, 2 H); 1.6 (m, 2 H); 1.3 (m, 2 H).


PROCEDURE S

**WWW**1-(Pyridin-3-yl)-1,3-butadiene

To a solution of 860 mL of 1 M sodium hexamethyldisilazide in THF was added 700 mL of dry THF and 361g (0.94 mole) of allyl triphenylphosphonium bromide at 0-5°C under argon. After stirring the mixture cold for 1 h, a solution of 91.8g (0.86 mole) of 3-pyridinecarboxaldehyde in 300 mL of dry THF was added portionwise keeping the reaction mixture below 15°C. After 3 h at 10°C, 100 mL of H₂O and 1000 mL of Et₂O were added. The organic layer was dried (MgSO₄) and then evaporated in vacuo to an oil. Flash chromatography (SiO₂) eluting with 20% acetone: 80% CH₂Cl₂ gave an oil. Kugelrohr distillation gave an oil: bp 55-79°C (0.005 Torr).

Mass spectrum (CI-CH₄) m/z 132 (m+1)

¹H NMR (CDCl₃) δ 5.12-5.28 (m, 1H); 5.29-5.42 (m, 1H); 6.22-6.51(m, 2H); 6.64-6.8 (m,1H); 7.11-7.22 (m,1H); 7.51-7.68 (m, 2H); 8.31-8.42 (m,1H); 8.48-8.58 (m,1H) .




2-Methyl-4α-(pyridin-3-yl)-3α,4,7,7α-tetrahydro-1H-isoindole-1,3(2H)-dione

A solution of 31.6g (0.24 mole) of 1-(pyridin-3-yl)-1,3-butadiene, WWW, and 27.3g (0.24 mole) of N-methylmaleimide in 82 mL of xylene was heated in a sealed bottle for 18h in an oil bath at 125°C. The xylene was evaporated in vacuo to an oily residue. The 2 diastereoisomers were separated using flash chromatography on SiO₂ eluting with 20% acetone: 80% CH₂Cl₂. The first compound that eluted was 2-methyl-4α-(pyridin-3-yl)-3α,4,7,7α-tetrahydroiso-1H-isoindole-1,3(2H)-dione as a yellow oil.

^1H NMR (CDCl_3): δ 2.4-2.6 (m, 2H); 3.1 (s, 3H); 3.12-3.22 (m, 1H); 3.22-3.3 (dd, 1H); 3.02-3.15 (m, 1H); 6.05-6.1 (m, 1H); 6.1-6.15 (m, 1H); 7.28-7.31 (m, 1H); 7.6-7.65 (d, 1H); 8.5-8.65 (m, 2H).

Exact Mass MH^+ calcd. 243.1134; found 243.1176.



2-Methyl-4 α -(pyridin-3-yl)-3 α ,7 α -hexahydro-1H-isoindole-1,3(2H)-dione


A solution of 4.04g (0.0166 mole) of 2-methyl-4 α -(pyridin-3-yl)-3 α ,4,7,7 α -tetrahydro-1H-isoindole-1,3(2H)-dione, VVV, in 100 mL of EtOAc was added to 4g of 10% palladium on carbon and placed on the Paar hydrogenator at 60 psi of hydrogen for 2 h. The catalyst was filtered off, and the filtrate evaporated in vacuo to give a solid: mp 110-112°C.

^1H NMR (CDCl_3) δ 1.35-1.90 (m, 5H); 2.2-2.3 (m, 1H); 2.65-2.72 (m, 1H); 3.0 (s, 3 H); 3.02-3.15 (m, 2H); 7.25-7.3 (m, 1H); 7.5-7.53 (dd, 1H); 8.50-8.55 (m, 2H).

Anal. calcd for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}_2$: C, 68.83; H, 6.60; N, 11.47

Found: C, 68.73; H, 6.64; N, 11.37

Example 23

Cp-332-Methyl-4α-(pyridin-3-yl)-3α,7α-octahydro-1H-isoindole Fumarate

- 5 To a solution of 13g (53 mM) of 2-methyl-4α-(pyridin-3-yl)-3α,7α-hexahydro-1H-isoindole-1,3(2H)-dione, UUU, in 130 mL of dry THF was added 400 mL of a solution of 1 M borane-THF under argon, and refluxed for 17 h. Then 28.8 mL of H₂O was added portionwise at room temperature. The solvent was evaporated in vacuo, and 300 mL of propionic acid added. After
- 10 refluxing for 6 h, the propionic acid was evaporated in vacuo, and 300 mL of 3N NaOH solution was added. After heating on a steam bath for 2 h, the reaction mixture was extracted with ether and the ether solution dried (K₂CO₃). The Et₂O was evaporated in vacuo to an oil. Flash
- 15 chromatography (SiO₂) eluting with 80 parts CH₂Cl₂: 20 parts MeOH: 2 parts ammonium hydroxide, gave 6.67g of a tan oil. The oil was dissolved in a MeOH solution containing 3.6g of fumaric acid. A sample was recrystallized from 2-PrOH to give a solid: mp 138- 140°C.


Mass spectrum (CI-CH₄) m/z 217 (m+1)

- 20 ¹H NMR (CDCl₃) : δ 1.42-1.78 (m, 6H); 2.32-2.5 (m, 1H); 2.61-2.83 (m, 6H); 2.91-3.02 (m, 1H); 3.03-3.15 (t, 1H); 3.30-3.45 (t, 1H); 6.5 (s, 2H); 7.28-7.35 (m, 1H); 7.63-7.72 (m, 1H); 8.38-8.45 (m, 1H); 8.46-8.51 (d, 1H).

Anal. calcd for C₁₄H₂₀N₂.C₄H₄O₄: C, 65.04 H, 7.28; N, 8.43

Found C, 65.01; H, 7.40; N, 8.52

Example 24




5 Employing the procedures of the foregoing example and starting with 4-bromobenzaldehyde in place of pyridinecarboxaldehyde, there was obtained: 4α-(4-bromophenyl)-2-methyl-3α,7α-octahydro-1H-isoindole fumarate: mp 222-224°C.

Anal. Calcd for C₁₅H₂₀BrN.C₄H₄O₄: C, 55.62; H, 5.90; N, 3.41

Found C, 55.65; H, 5.92 N, 3.35

10

Example 25



4β-(3,4-dichlorophenyl)-3α,7α-octahydro-1H-isoindole

15 Employing a minor variation of the procedure of Example 3 wherein the solvent for the Diels-Alder step was refluxing acetonitrile, substituting 3,4-dichlorobenzaldehyde for 3-methoxybenzaldehyde in the Wittig step and substituting maleimide for N-methylmaleimide in the Diels-Alder step, there


2159071

was obtained 4 β -(3,4-dichlorophenyl)-3 α ,7 α -octahydro-1H-isoindole fumarate: mp 166-169°C.

Anal. calcd for: C₁₄H₁₇Cl₂N-C₄H₄O₄:C, 55.97; H, 5.48; N, 3.63.

Found: C, 55.94; H, 5.48; N, 3.62.

5

Procedure T**SSS**


[4 β -(3,4-Dichlorophenyl)-3 α ,7 α -octahydro-1H-isoindol-2-yl]-cyclopropylmethanone

- 10 To a mixture of 150 mg (0.5 mM) of 4 β -(3,4-dichlorophenyl)-3 α ,7 α -octahydro-1H-isoindole hydrochloride, Cp-35, in 5 mL of CH₂Cl₂ was added 1.5 mL of 1N NaOH solution and 3.5 mL of H₂O. Then, 52 mg (0.5 mM) of cyclopropanecarbonyl chloride was added and the mixture stirred for 30 min. The CH₂Cl₂ layer was separated, dried (Na₂SO₄), and evaporated
- 15 in vacuo to give 170 mg of an oil. Flash chromatography (SiO₂) eluting with 20% acetone: 80% hexane, gave a white solid.

Mass spectrum (CI-CH₄) m/z 338(M+1)

- H¹NMR (CDCl₃/ D₂O): δ 0.65-0.82 (m, 2H); 0.83-1.08 (m, 2H); 1.4-1.61 (m, 3H); 1.62-1.86 (m, 3H); 1.87-2.09 (m, 1H); 2.18-2.4 (m, 1H); 2.5-2.8 (m, 1H);
- 20 2.92-3.18 (m, 2H); 3.19-3.32 (t, 1H); 3.33-3.52 (m, 2H); 3.65-3.80 (m, 1H); 7.0-7.1(m, 1H); 7.2-7.4 (m, 2H).

Example 26

Cp-37

5 2-Cyclopropylmethyl-4 β -(3,4-dichlorophenyl)-3 α ,7 α -octahydro-1H-
isoindole Oxalate.

To a solution of 890 mg (2.65 mM) of [4 β -(3,4-dichlorophenyl)-3 α ,7 α -octahydro-1H-isoindol-2-yl]-cyclopropyl-methanone, **SSS**, in 10 mL of dry THF was added 13.2 mL of 1 M borane/THF solution and refluxed for 17 h. Then 1 mL of H₂O was added to the reaction mixture at room temperature and stirred for 10 min. The THF was evaporated in vacuo and 3.2 mL of propionic acid added. The mixture was refluxed for 6 h, then basified with 3N NaOH solution, and extracted with CH₂Cl₂. The CH₂Cl₂ solution was dried (K₂CO₃), and evaporated in vacuo to a yellow oil. Flash chromatography (SiO₂) eluting with 10% MeOH: 90% CH₂Cl₂ gave an oil which was partitioned between 3N NaOH solution and ether. The ether solution was dried (K₂CO₃) and evaporated in vacuo to an oil. The oil was dissolved in a MeOH solution containing 130 mg oxalic acid, and the salt was recrystallized from 2-PrOH to give a white solid: mp 159-163°C.


Mass spectrum (CI-CH₄) m/z 324(m+1)

¹H NMR (Me₂SO-d₆) : δ 0.2-0.35 (m, 2H); 0.4-0.6 (m, 2H); 0.88-1.02 (m, 1H); 1.18-1.45 (m, 2H); 1.5-1.68 (m, 2H); 1.69-1.88 (m, 2H); 2.2-2.4 (m, 1H); 2.58-2.78 (m, 2H); 2.8-3.05 (m, 2H); 3.06-3.2 (m, 2H); 3.25-3.5 (m, 2H); 7.22-7.3 (dd, 1H); 7.4-7.6 (m, 2H).

Anal. Calcd for C₁₈H₂₃Cl₂N.C₂H₂O₄: C, 57.98; H, 6.08; N, 3.38

Found: C, 58.01; H, 6.11; N, 3.38

Example 27

Cp-38

5 2-Cyclohexyl-4β-(3,4-dichlorophenyl)-3α,7α-octahydro-1H-
isoindole Fumarate

10 To a solution of 780 mg (2.9 mM) of 4β-(3,4-dichlorophenyl)-3α,7α-octahydro-1H-isoindole, Cp-35, and 284 mg (2.89 mmol) of cyclohexanone in 10 mL of dry 1,2-dichloroethane was added 68 mg (2.9 mM) of sodium triacetoxyborohydride and 0.16 mL of glacial HOAc and stirred at room temperature overnight. The reaction was basified with 3N NaOH solution, and extracted with CH₂Cl₂. The CH₂Cl₂ solution was washed with brine, dried (K₂CO₃), and evaporated in vacuo to an oil. The oil was dissolved in a solution of 2-PrOH containing 277 mg of fumaric acid, and the salt recrystallized from MeOH-acetonitrile to give a solid: mp 221°C.

15 Mass spectrum (CI-CH₄) m/z 352(m+1)


¹H NMR (CDCl₃) : δ 1.0-1.5 (m, 8H); 1.5-1.95 (m, 8H); 2.05-2.2 (m, 3H); 2.4-2.45 (d, 1H); 2.5-2.52 (m, 2H); 2.9-3.05 (m, 2H); 7.0-7.08 (dd, 1H); 7.25-7.35 (m, 2H).

Anal. Calcd for C₂₀H₂₇Cl₂N-C₄H₄O₄: C, 61.54; H, 6.67; N, 2.99

20

Found: C, 61.37; H, 6.64; N, 3.00

Example 28

Cp-39

4β-(3,4-dichlorophenyl)-2-methylethyl-3α,7α-octahydro-1H-isoindole


- 5 Employing the procedure of the foregoing example and starting with acetone in place of cyclohexanone, there was obtained: 4β-(3,4-dichlorophenyl)-2-methylethyl-3α,7α-octahydro-1H-isoindole fumarate: mp 207-210 °C.

anal. calcd for: C₁₇H₂₃Cl₂N-C₄H₄O₄:C, 58.88; H, 6.35; N, 3.27.

Found: C, 58.60; H, 6.61; N, 3.24.

10

Example 29

Cp-40

4β-Cyanophenyl-2-methyl-3α,7α-octahydro-1H-isoindole fumarate
hydrate (6:6:1)

- 15 A solution of 2.0 g (6.85 mmol) of 4β-bromophenyl-2-methyl-3α,7α-octahydro-1H-isoindole, Cp-44 1.14 g (10.73 mmol) of CuCN and 39 mg (0.034 mmol) of tetrakis(triphenylphosphine)palladium(0) in 7.0 mL of


pyridine under argon was heated under reflux for 3 days. The mixture was cooled and partitioned between Et₂O and NH₄OH. The organic solution was dried (K₂CO₃) and the solvent evaporated. The residue was recrystallized twice from methyl *t*-butyl ether/methylcyclohexane. A fumarate salt was prepared and was recrystallized successively from 2-PrOH and MeOH to afford the title compound as a white solid: mp 198-200°C.

¹H NMR (Me₂SO-d₆) δ 7.8 (dd, 2H), 7.45 (dd, 2H), 6.47 (s, 2H), 3.3-3.1 (m, 3H), 2.95 (dd, 1H), 2.73 (m, 1H), 2.55 (s, 3H), 2.3 (m, 2H), 1.8 (m, 2H), 1.62 (m, 2H), 1.36 (m, 2H).

Anal. calcd for C₁₆H₂₀N₂·C₄H₄O₄·0.167 H₂O: C, 66.83; H, 6.82; N, 7.79.
Found: C, 66.68; H, 6.84; N, 7.69.

Example 30

Employing the procedures of Examples 1 and 2 and substituting 2'-chlorocinnamoyl chloride or 2',6'-dichlorocinnamoyl chloride for *m*-trifluoromethylcinnamoyl chloride, the following compounds were obtained:




Cp-41

4α-(2-Chlorophenyl)-2-methyl-3α,7α-octahydro-1H-isoindole fumarate.

mp 168-17 °C.

Anal. calcd for: C₁₅H₂₀ClN·C₄H₄O₄: C, 62.19; H, 6.85; N, 3.77.
Found: C, 62.38; H, 6.61; N, 3.83.

Cp-42

4α-(2,6-Dichlorophenyl)-2-methyl-3α,7α-octahydro-1H-isoindole
di(cyclohexylsulfamate)


5 mp 128-129°C.

Anal. calcd for: C₁₅H₁₉ClN-C₄H₄O₄:C, 50.45; H, 7.06; N, 6.54.

Found: C, 50.26; H, 7.05; N, 6.53.

Example 31

10 Employing the procedure of Example 3 or a minor variation thereof wherein the solvent for the Diels-Alder step was refluxing acetonitrile (aryl = *p*-bromophenyl, 3,4-dichlorophenyl and 3-pyridyl) and substituting the appropriate 1-aryl-1,3-butadiene for 3-methoxyphenyl-1,3-butadiene, the following compounds were obtained:

Cp-43


2-Methyl-4β-(phenyl)-3α,7α-octahydro-1H-isoindole fumarate.

mp 152-153°C.

Anal. calcd for: C₁₅H₂₁N-C₄H₄O₄:C, 68.86; H, 7.60; N, 4.23.

Found: C, 68.87; H, 7.46; N, 4.14.

2159071




4β-(4-Bromophenyl)-2-methyl-3α,7α-octahydro-1H-isoindole fumarate.

mp 193-194 °C.

5 Anal. calcd for: C₁₅H₂₀BrN-C₄H₄O₄: C, 55.62; H, 5.90; N, 3.41.

Found: C, 55.67; H, 5.94; N, 3.40.




2-Methyl-4β-(pyridin-3-yl)-3α,7α-octahydro-1H-isoindole fumarate
10 hydrate (5:5:3)

mp 152-153 °C.

Anal. calcd for: C₁₄H₂₀N₂-C₄H₄O₄-0.6 H₂O: C, 62.99; H, 7.40; N, 8.16;
H₂O, 3.14.

Found: C, 62.81; H, 7.04; N, 7.95; H₂O, 2.64.



4β-(3,4-Dichlorophenyl)-2-methyl-3α,7α-octahydro-1H-isoindole fumarate.


5 mp 158-165°C.

Anal. calcd for: C₁₅H₁₉Cl₂N-C₄H₄O₄: C, 57.01; H, 5.79; N, 3.50.

Found: C, 56.82; H, 5.85; N, 3.49.

Example 32

10 Employing the procedure of Example 10 and substituting isopropylamine for methylamine, the following compound was obtained:



4α-(4-Fluorophenyl)-5α-methyl-2-methylethyl-3α,7α-octahydro-1H-isoindole fumarate.


15 mp 215-216°C.

Anal. calcd for: C₁₈H₂₆FN-C₄H₄O₄: C, 67.49; H, 7.72; N, 3.57.

Found: C, 67.65; H, 8.02; N, 3.45.

Example 33

Employing the procedure of Example 10 and 12 and substituting isopropylamine for methylamine, the following compound was obtained:

**Cp-48**

4α-(4-Fluorophenyl)-5α-methyl-2-methylethyl-2,3,3aα,4,5,7aβ-hexahydro-1H-isoindole fumarate.


mp 208-211°C.

Anal. calcd for: C₁₈H₂₄FN-C₄H₄O₄: C, 67.85; H, 7.24; N, 3.60.

Found: C, 67.58; H, 7.46; N, 3.50.

Example 34

Employing the procedure of Example 10 (Procedure I) and substituting isopropylamine for methylamine, then treating the intermediate analogous to compound YY wherein the methyl group on nitrogen is replaced with isopropyl with LAH as in Example 12 the following compound was obtained:

**Cp-49**

4 α -(4-Fluorophenyl)-5 β -methyl-2-methylethyl-2.3.3 α .4.5.7 α -hexahydro-1H-isoindole fumarate.

mp 184-185°C.


Anal. calcd for: C₁₈H₂₄FN-C₄H₄O₄: C, 67.85; H, 7.24; N, 3.60.

Found: C, 67.72; H, 7.11; N, 3.53.

5

Example 35

Employing the procedures of Example 14 and 15 (Procedure L) and starting with 1-phenyl-1,3-butadiene in place of 1-(3-methylphenyl)-1,3-butadiene, the following compounds were obtained:



Cp-50

10


2-(1,1-dimethylethyl)-4 β -(phenyl)-3 α .7 α -octahydro-1H-isoindole fumarate.

mp 214-216 °C.

Anal. calcd for: C₁₈H₂₇N-C₄H₄O₄: C, 70.75; H, 8.37; N, 3.75.

Found: C, 70.89; H, 8.41; N, 3.73.

15



Cp-51

2-Cyclopropyl-4 β -(phenyl)-3 α .7 α -octahydro-1H-isoindole fumarate.


mp 148-152°C.

Anal. calcd for: C₁₇H₂₃N-C₄H₄O₄: C, 70.56; H, 7.61; N, 3.91.

Found: C, 70.22; H, 7.75 N, 3.79.

Example 36

- 5 Employing the procedure of Example 16 (Procedure M) and starting with 1-phenyl-1,3-butadiene in place of 1-(4-methylthiophenyl)-1,3-butadiene, the following compounds were obtained:




Cp-52

- 10 2-Methyl-4α-phenyl-2.3.3α.4.7.7α-hexahydro-1H-isoinidole fumarate.

mp 123-127°C.

Anal. calcd for: C₁₅H₁₉N-C₄H₄O₄: C, 69.28; H, 7.04; N, 4.25.

Found: C, 68.99; H, 6.99; N, 4.28.



Cp-53

15

- 2-Methyl-4β-phenyl-2.3.3α.4.7.7α-hexahydro-1H-isoinidole fumarate.


mp 153-155° C

Anal. calcd for C₁₅H₁₉N-C₄H₄O₄: C, 69.28; H, 7.04; N, 4.25.


Found: C, 69.00; H, 7.22; N, 4.14.

WHAT IS CLAIMED IS:

1. A compound having analgesic activity of the general formula:



- 5 or a purified stereoisomer or pharmaceutically acceptable salts thereof, wherein:



- 10 R^{a1} is selected from the group consisting of hydroxy, halogen, C₁-4alkyl, substituted C₁-4alkyl (wherein the substituent is C₁-4alkoxy, hydroxy or perhalo), C₁-4alkoxy, substituted C₁-4alkoxy (wherein the substituent is perfluoro), C₁-4alkylthio, cyano, nitro, amino, C₁-4alkylamino, diC₁-4alkylamino, C₁-4alkylsulfonyl, C₁-4alkylsulfinyl, phenyl, phenylthio, C₁-4acylamino, carboxy, C₁-4acyl and benzoyl;

- 15 R^{a2} is selected from the group consisting of halogen or C₁-4alkyl;

R^b is 5-, 6-, or 7-position substituted and selected from the group consisting of hydrogen and C₁-4 alkyl; and

- 20 R^c is selected from the group consisting of hydrogen, C₁-4 alkyl, substituted C₁-4alkyl (wherein the substituent is one or two phenyl groups or diC₁-4alkylamino), C₂-4alkenyl, benzyl, C₃-6cycloalkylmethyl and C₃-6cycloalkyl;


with the proviso that there is 0 or 1 unsaturated bond in the isoindole ring
and with the proviso that where the stereoisomer is:

a) the $3a\beta$, 4β , $7a\alpha$ diastereomer, then a double bond joins the 5- and 6-position carbons or the 6- and 7-position carbons;

5 b) the $3a\beta$, 4α , $7a\alpha$ or the $3a\beta$, 4α , $7a\beta$ diastereomers, then the double bond joins the 5- and 6-position carbons; and

c) the $3a\beta$, 4β , $7a\beta$ diastereomer, then the double bond joins the 6- and 7-position carbons.


2. A compound of claim 1 of the general formula:



10


or a purified stereoisomer thereof.

3. A compound of claim 1 of the general formula:




or a purified stereoisomer thereof.

4. A compound of claim 1 of the general formula:



or a purified stereoisomer thereof.


5. A compound of claim 1 of the general formula:



5


or a purified stereoisomer thereof.

6. A compound of claim 1 of the general formula:




or a purified stereoisomer thereof.

7. A compound of claim 1 of the general formula:



or a purified stereoisomer thereof.

8. A compound of claim 1 wherein:



5

9. A compound of claim 1 wherein:

R^{a1} is selected from the group consisting of hydroxy, bromine, chlorine, fluorine, methyl, ethyl, n-propyl, i-propyl, t-butyl, methoxymethyl, ethoxyethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, trifluoromethyl, trichloromethyl, methoxy, ethoxy, t-butoxy, trifluoromethoxy, methylthio, ethylthio, n-propylthio, cyano, nitro, amino, methylamino, ethylamino, n-propylamino, dimethylamino, diethylamino, methylethylamino, methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, methylsulfinyl, ethylsulfinyl, n-propylsulfinyl, phenyl, phenylthio, formylamido, acetamido, propionylamido, carboxy, formyl, acetyl, propionyl and benzoyl.

10

15

10. A compound of claim 1 wherein:

R^{a2} is selected from the group consisting of bromine, chlorine, fluorine, methyl, ethyl, n-propyl, i-propyl and t-butyl.

20

11. A compound of claim 1 wherein:


R^b is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, i-propyl and t-butyl.

12. A compound of claim 1 wherein:

5 R^c is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, i-propyl, t-butyl, benzyl, diphenylmethyl, dimethylaminomethyl, dimethylaminoethyl, dimethylaminopropyl, diethylaminomethyl, diethylaminoethyl, allyl, benzyl, cyclopropylmethyl, cyclopropyl and cyclohexylmethyl.

10 13. A compound of claim 1 wherein said pharmaceutically acceptable salt is the salt of an acid selected from the group consisting of hydrochloric, hydrobromic, hydroiodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-
15 naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic and saccharic.

14. A compound selected from the group consisting of:




20 wherein R^a , R^b and R^c are simultaneously selected from the group consisting of:


R^a	R^b	R^c
4'-F	5-Me	Me,
3'-methoxy	H	Me,
3'-methoxy	H	H,
25 3'-CF ₃	H	Me,





	3'-methoxy	H	benzyl,
	2',3'-dimethoxy	H	Me,
	3',4'-dichloro	H	Me,
	3'-OH	H	Me,
5	-	H	Me,
	4'-CF ₃	H	Me,
	3'-CF ₃	H	n-butyl,
	4'-NO ₂	H	Me,
	4'-NH ₂	H	Me,
10	4'-NHCOCH ₃	H	Me,
	4'-Cl	H	Me,
	2'-Cl	H	Me,
	2',5'-Cl	H	Me,
	4'-F	H	Me,
15	4'-methoxy	H	Me,
	3',4'-dimethoxy	H	Me,
	4'-i-propyl	H	Me,
	4'-CN	H	Me,
	4'-Br	H	Me,
20	4'-SMe	H	Me,
	4'-SO ₂ Me	H	Me, and
	3'-methoxy	H	benzyl,


or a purified stereoisomer thereof.





15. A compound selected from the group consisting of:















or a purified stereoisomer thereof.

16. A compound of claim 15 selected from the group consisting of:



5 17. A pharmaceutical composition effective as an analgesic in mammals comprising a pharmaceutically acceptable carrier and an effective amount of a compound of claim 1.

18. Use of a compound of claim 1 for inducing an analgesic effect in a mammal.

10

19. Use of a pharmaceutical composition of claim 17 for inducing an analgesic effect in a mammal.

